<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title>PLoS ONE</journal-title><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">09-PONE-RA-09537R2</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0005926</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Immunology</subject><subject>Immunology/Antigen Processing and Recognition</subject><subject>Immunology/Immune Response</subject><subject>Immunology/Innate Immunity</subject><subject>Immunology/Leukocyte Activation</subject><subject>Pathology/Immunology</subject></subj-group></article-categories><title-group><article-title>A Functional &#x003b3;&#x003b4;TCR/CD3 Complex Distinct from &#x003b3;&#x003b4;T Cells Is Expressed by Human Eosinophils</article-title><alt-title alt-title-type="running-head">Eosinophil &#x003b3;&#x003b4;TCR Expression</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Legrand</surname><given-names>Fanny</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Driss</surname><given-names>Virginie</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Woerly</surname><given-names>Ga&#x000eb;tane</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Loiseau</surname><given-names>Sylvie</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hermann</surname><given-names>Emmanuel</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Fourni&#x000e9;</surname><given-names>Jean-Jacques</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>H&#x000e9;liot</surname><given-names>Laurent</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mattot</surname><given-names>Virginie</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Soncin</surname><given-names>Fabrice</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gougeon</surname><given-names>Marie-Lise</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Dombrowicz</surname><given-names>David</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="author-notes" rid="fn1"><sup>&#x000b6;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Capron</surname><given-names>Monique</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref><xref ref-type="author-notes" rid="fn1"><sup>&#x000b6;</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Inserm U547, Lille, France</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Universit&#x000e9; Lille - Nord de France, Lille, France</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Institut Pasteur de Lille, Lille, France</addr-line></aff><aff id="aff4"><label>4</label><addr-line>Inserm, U 563, Toulouse, France</addr-line></aff><aff id="aff5"><label>5</label><addr-line>CNRS UMR8161, Institut de Biologie de Lille, Lille, France</addr-line></aff><aff id="aff6"><label>6</label><addr-line>Institut Pasteur, Paris, France</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Unutmaz</surname><given-names>Derya</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">New York University School of Medicine, United States of America</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>monique.capron@pasteur-lille.fr</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: FL VD GW FS DDD MC. Performed the experiments: FL VD GW SL EH LH VM FS. Analyzed the data: FL VD GW SL JJF MLG DDD MC. Contributed reagents/materials/analysis tools: JJF. Wrote the paper: DDD MC.</p></fn><fn id="fn1" fn-type="other"><p>&#x000b6; These authors also contribued equally to this work.</p></fn></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>17</day><month>6</month><year>2009</year></pub-date><volume>4</volume><issue>6</issue><elocation-id>e5926</elocation-id><history><date date-type="received"><day>1</day><month>4</month><year>2009</year></date><date date-type="accepted"><day>13</day><month>5</month><year>2009</year></date></history><copyright-statement>Legrand et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement><copyright-year>2009</copyright-year><abstract><sec><title>Background</title><p>Eosinophils are effector cells during parasitic infections and allergic responses. However, their contribution to innate immunity has been only recently unravelled.</p></sec><sec><title>Methodology/Principal Findings</title><p>Here we show that human eosinophils express CD3 and &#x003b3;&#x003b4; T Cell Receptor (TCR) but not &#x003b1;&#x003b2; TCR. Surface expression of &#x003b3;&#x003b4;TCR/CD3 is heterogeneous between eosinophil donors and inducible by mycobacterial ligands. Surface immunoprecipitation revealed expression of the full &#x003b3;&#x003b4;TCR/CD3 complex. Real-time PCR amplification for CD3, &#x003b3; and &#x003b4; TCR constant regions transcripts showed a significantly lower expression in eosinophils than in &#x003b3;&#x003b4;T cells. Limited TCR rearrangements occur in eosinophils as shown by spectratyping analysis of CDR3 length profiles and <italic>in situ</italic> hybridization. Release by eosinophils of Reactive Oxygen Species, granule proteins, Eosinophil Peroxidase and Eosinophil-Derived Neurotoxin and cytokines (IFN-&#x003b3; and TNF-&#x003b1;) was observed following activation by &#x003b3;&#x003b4;TCR-specific agonists or by mycobacteria. These effects were inhibited by anti-&#x003b3;&#x003b4;TCR blocking antibodies and antagonists. Moreover, &#x003b3;&#x003b4;TCR/CD3 was involved in eosinophil cytotoxicity against tumor cells.</p></sec><sec><title>Conclusions/Significance</title><p>Our results provide evidence that human eosinophils express a functional &#x003b3;&#x003b4;TCR/CD3 with similar, but not identical, characteristics to &#x003b3;&#x003b4;TCR from &#x003b3;&#x003b4;T cells. We propose that this receptor contributes to eosinophil innate responses against mycobacteria and tumors and may represent an additional link between lymphoid and myeloid lineages.</p></sec></abstract><counts><page-count count="16"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Eosinophils are polymorphonuclear granulocytes mainly found in increased numbers during helminth parasitic infections and allergic reactions <xref ref-type="bibr" rid="pone.0005926-Giembycz1">&#x0005b;1&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005926-Rothenberg1">&#x0005b;2&#x0005d;</xref>. They are classically considered as mediator-releasing cells during effector phase of adaptive immunity, under the influence of T cell dependent cytokines or chemokines and antibodies <xref ref-type="bibr" rid="pone.0005926-Rothenberg1">&#x0005b;2&#x0005d;</xref>, whereas eosinophil-derived chemokines have been recently shown to locally attract Th2 lymphocytes at lung inflammatory sites <xref ref-type="bibr" rid="pone.0005926-Jacobsen1">&#x0005b;3&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005926-Walsh1">&#x0005b;4&#x0005d;</xref>. Nevertheless, their precise function as beneficial or deleterious to the host still remains ambiguous, since highly toxic proteins present in eosinophil granules exert potent cytotoxic effects against non self targets such as parasites <xref ref-type="bibr" rid="pone.0005926-Young1">&#x0005b;5&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005926-Gounni1">&#x0005b;6&#x0005d;</xref> but also against stressed or necrotic host cells <xref ref-type="bibr" rid="pone.0005926-Stenfeldt1">&#x0005b;7&#x0005d;</xref> and in asthma <xref ref-type="bibr" rid="pone.0005926-Jacobsen2">&#x0005b;8&#x0005d;</xref>. Eosinophils are foremost present in mucosal tissues in contact with the environment such as in gastro-intestinal tract and skin <xref ref-type="bibr" rid="pone.0005926-Rothenberg1">&#x0005b;2&#x0005d;</xref> and are characterized by their wide morphological and functional heterogeneity <xref ref-type="bibr" rid="pone.0005926-Kayaba1">&#x0005b;9&#x0005d;</xref>.</p><p>In addition to these effector functions, eosinophils produce several Th1, Th2 and regulatory cytokines, such as IL-10 <xref ref-type="bibr" rid="pone.0005926-Woerly1">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005926-Woerly2">&#x0005b;11&#x0005d;</xref>, which, in contrast to T cells, are stored within granules and promptly released upon activation <xref ref-type="bibr" rid="pone.0005926-Melo1">&#x0005b;12&#x0005d;</xref>. Eosinophils also express MHCII and CD86 <xref ref-type="bibr" rid="pone.0005926-Woerly1">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005926-Lucey1">&#x0005b;13&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005926-Seton1">&#x0005b;14&#x0005d;</xref> and act as antigen-presenting cells <xref ref-type="bibr" rid="pone.0005926-Shi1">&#x0005b;15&#x0005d;</xref>. Furthermore, eosinophils share with T cells expression of various receptors such as CD25 <xref ref-type="bibr" rid="pone.0005926-Plumas1">&#x0005b;16&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005926-Simon1">&#x0005b;17&#x0005d;</xref>, CD4 <xref ref-type="bibr" rid="pone.0005926-Lucey2">&#x0005b;18&#x0005d;</xref>, CD28 <xref ref-type="bibr" rid="pone.0005926-Woerly1">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005926-Seton1">&#x0005b;14&#x0005d;</xref> and several members of the CD2 family, including 2B4 <xref ref-type="bibr" rid="pone.0005926-Munitz1">&#x0005b;19&#x0005d;</xref>. This wide array of molecules endows eosinophils with the ability to induce and regulate adaptive immunity.</p><p>However, the early appearance of eosinophils in agnathans, predating the appearance of the classical adaptive immune system <xref ref-type="bibr" rid="pone.0005926-Rowley1">&#x0005b;20&#x0005d;</xref> and the expression by eosinophils of several receptors involved in innate immunity, such as formyl peptide receptor <xref ref-type="bibr" rid="pone.0005926-Svensson1">&#x0005b;21&#x0005d;</xref>, protease-activated receptors <xref ref-type="bibr" rid="pone.0005926-Miike1">&#x0005b;22&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005926-Bolton1">&#x0005b;23&#x0005d;</xref> and TLR <xref ref-type="bibr" rid="pone.0005926-Driss1">&#x0005b;24&#x0005d;</xref> further point toward a role for eosinophils in innate immunity. Eosinophils contribute to TLR-mediated immunity against viruses and mycobacteria <xref ref-type="bibr" rid="pone.0005926-Nagase1">&#x0005b;25&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005926-Phipps1">&#x0005b;26&#x0005d;</xref>. Indeed, we recently showed that TLR-2-dependent activation of human eosinophils induced &#x003b1;-defensin and ECP release and decreased mycobacteria growth <xref ref-type="bibr" rid="pone.0005926-Driss1">&#x0005b;24&#x0005d;</xref>. Furthermore, expulsion of mitochondrial DNA by eosinophils has been shown to contribute to innate immune defences against bacteria <xref ref-type="bibr" rid="pone.0005926-Yousefi1">&#x0005b;27&#x0005d;</xref>. Finally, eosinophil-tumor cell interactions and IL-4-dependent tumoricidal activity of eosinophils have been reported <xref ref-type="bibr" rid="pone.0005926-Tepper1">&#x0005b;28&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005926-Tepper2">&#x0005b;29&#x0005d;</xref>. Thus eosinophils appear functionally located at the interface between innate and adaptive immunity.</p><p>Strikingly, &#x003b3;&#x003b4;T cells are ancestral to other lymphoid populations such as &#x003b1;&#x003b2;T cells and B cells, they participate to both innate and adaptive immune responses, have a preferential mucosal localisation and might act as professional antigen-presenting cells <xref ref-type="bibr" rid="pone.0005926-Brandes1">&#x0005b;30&#x0005d;</xref> recognizing non-peptide antigens found on several pathogens, including mycobacteria, necrotic and tumor cells <xref ref-type="bibr" rid="pone.0005926-Hayday1">&#x0005b;31&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005926-Carding1">&#x0005b;32&#x0005d;</xref>.</p><p>These surprising similarities between &#x003b3;&#x003b4;T cells and eosinophils prompted us to investigate, whether, in addition to other T cell-associated receptors, human eosinophils expressed a &#x003b3;&#x003b4;T cell Receptor (TCR). We here report that human blood eosinophils express low levels of surface &#x003b3;&#x003b4;TCR/CD3, inducible by mycobacterial ligands. We show that eosinophils release granule proteins and cytokines upon activation by &#x003b3;&#x003b4;TCR agonists, including mycobacteria. Furthermore, we provide evidence that &#x003b3;&#x003b4;TCR contributes to eosinophil cytotoxic potential towards tumors.</p></sec><sec id="s2"><title>Results</title><sec id="s2a"><title>Human eosinophils express CD3 and &#x003b3;&#x003b4;TCR but not &#x003b1;&#x003b2;TCR</title><p>In order to investigate expression by human blood eosinophils of T cell associated receptors, we purified eosinophils by negative selection using magnetic beads. These highly purified eosinophils (<xref ref-type="supplementary-material" rid="pone.0005926.s001">Figure S1A</xref>) expressed specific granule proteins such as eosinophil peroxidase (EPO) and major basic protein (MBP) but not myeloperoxidase (MPO) associated to neutrophil and monocyte/macrophage lineages <xref ref-type="bibr" rid="pone.0005926-Metso1">&#x0005b;33&#x0005d;</xref> (<xref ref-type="supplementary-material" rid="pone.0005926.s001">Figure S1B</xref>). Lymphocytes expressed neither of these myeloid markers (<xref ref-type="supplementary-material" rid="pone.0005926.s001">Figure S1B</xref>).</p><p>Following permeabilization, binding of anti-CD3 but not anti-CD8 antibodies was detected in eosinophils (<xref ref-type="fig" rid="pone-0005926-g001">Figure 1A</xref>). In T cells, CD3 associates with either &#x003b1;&#x003b2;TCR or &#x003b3;&#x003b4;TCR. We did not detect &#x003b1;&#x003b2;TCR on eosinophils but &#x003b3;&#x003b4;TCR expression was evidenced (<xref ref-type="fig" rid="pone-0005926-g001">Figure 1A</xref>). While lymphocytes from PBMC fraction expressed these markers at the expected frequencies (<xref ref-type="fig" rid="pone-0005926-g001">Figure 1B</xref>) and unlike a previous report <xref ref-type="bibr" rid="pone.0005926-Puellmann1">&#x0005b;34&#x0005d;</xref>, we were unable to detect CD3 or &#x003b1;&#x003b2;TCR expression in neutrophils (<xref ref-type="fig" rid="pone-0005926-g001">Figure 1C</xref>). Likewise neither CD8 nor &#x003b3;&#x003b4;TCR expression was detected in neutrophils (<xref ref-type="fig" rid="pone-0005926-g001">Figure 1C</xref>).</p><fig id="pone-0005926-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005926.g001</object-id><label>Figure 1</label><caption><title>Expression of &#x003b3;&#x003b4;TCR/CD3 complex by human eosinophils.</title><p>(A&#x02013;C) CD3, CD8, &#x003b1;&#x003b2;TCR and &#x003b3;&#x003b4;TCR expression on permeabilized cells gated as described in <xref ref-type="supplementary-material" rid="pone.0005926.s001">Figure S1</xref> (A) purified peripheral blood eosinophils (B) lymphocytes and (C) neutrophils. Staining with control isotype matched antibodies is represented in white histograms.</p></caption><graphic xlink:href="pone.0005926.g001"/></fig><p>Surface expression of CD3 and &#x003b3;&#x003b4;TCR was detected on a fraction of eosinophils following double staining with antibodies against two specific eosinophil granule proteins EPO (<xref ref-type="fig" rid="pone-0005926-g002">Figure 2A</xref>) or MBP (<xref ref-type="fig" rid="pone-0005926-g002">Figure 2B</xref>). Similarly to intracellular staining, neither CD8 nor &#x003b1;&#x003b2;TCR were detected at eosinophil surface. By contrast, another &#x003b3;&#x003b4;T cell marker, NKG2D, was expressed in a lower proportion of cells (<xref ref-type="fig" rid="pone-0005926-g002">Figure 2A&#x02013;B</xref>). As CD3 is required for receptor complex surface expression, CD3<sup>&#x0002b;</sup>&#x003b3;&#x003b4;TCR<sup>&#x0002b;</sup> eosinophils were thus identified following triple staining (<xref ref-type="fig" rid="pone-0005926-g002">Figure 2C</xref>). In human blood, &#x003b3;&#x003b4;T cells express either V&#x003b3;9/V&#x003b4;2 or V&#x003b4;1 variable regions. We also evidenced that EPO<sup>&#x0002b;</sup> or MBP<sup>&#x0002b;</sup> eosinophils expressed V&#x003b3;9, V&#x003b4;1 and V&#x003b4;2 and unexpectedly co-expressed V&#x003b4;1 and V&#x003b4;2 at their surface (<xref ref-type="fig" rid="pone-0005926-g002">Figure 2A&#x02013;C</xref>).</p><fig id="pone-0005926-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005926.g002</object-id><label>Figure 2</label><caption><title>Surface expression of &#x003b3;&#x003b4;TCR/CD3 complex by human eosinophils.</title><p>(A&#x02013;C) CD3, &#x003b3;&#x003b4;TCR, V&#x003b3;9, V&#x003b4;2, V&#x003b4;1, &#x003b1;&#x003b2;TCR, CD8 and NKG2D surface expression on EPO<sup>&#x0002b;</sup> (A) and MBP2<sup>&#x0002b;</sup> (B) purified peripheral blood eosinophils analysed after 18 h culture and gated as described in <xref ref-type="supplementary-material" rid="pone.0005926.s001">Figure S1</xref>. Results in (A) and (B) represent to 2 distinct representative donors. Staining with control isotype antibodies is represented. (C) Presence of CD3<sup>&#x0002b;</sup>&#x003b3;&#x003b4;TCR<sup>&#x0002b;</sup>EPO<sup>&#x0002b;</sup> and V&#x003b4;1<sup>&#x0002b;</sup>&#x003b4;2<sup>&#x0002b;</sup>EPO<sup>&#x0002b;</sup> eosinophils identified by triple staining. Staining with control isotype matched antibodies as well as corresponding double stainings is represented.</p></caption><graphic xlink:href="pone.0005926.g002"/></fig><p>Expression of &#x003b3;&#x003b4;TCR/CD3 complex was investigated in healthy donors and patients with either reactive eosinophilia (allergies, various skin diseases) or hypereosinophilic syndrome (HES). A wide heterogeneity of surface expression of &#x003b3;&#x003b4;TCR/CD3 and NKG2D was not only found among the 23 donors but also within each group, including healthy donors, however no correlation was observed between receptor expression levels and either eosinophilia, or a specific pathology (<xref ref-type="fig" rid="pone-0005926-g003">Figure 3A&#x02013;B</xref>).</p><fig id="pone-0005926-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005926.g003</object-id><label>Figure 3</label><caption><title>Heterogeneity of surface expression of &#x003b3;&#x003b4;TCR/CD3 complex by human eosinophils.</title><p>(A) Cell surface marker expression on EPO<sup>&#x0002b;</sup> gated peripheral blood eosinophils from 23 individual eosinophil donors. Group average expression for the indicated markers is represented (-). (B) Individual data and patient status.</p></caption><graphic xlink:href="pone.0005926.g003"/></fig><p>Following <italic>in vitro</italic> activation of &#x003b3;&#x003b4;T cells, CD3, CD8, &#x003b3;&#x003b4;TCR as well as V&#x003b3;9, V&#x003b4;2 and V&#x003b4;1 were detected at the expected frequencies (<xref ref-type="supplementary-material" rid="pone.0005926.s002">Figure S2A</xref>). Likewise, freshly isolated PBMC from the same eosinophil donors, in which &#x003b3;&#x003b4;T cells represent a very minor population, expressed CD3, &#x003b1;&#x003b2;TCR or low levels of &#x003b3;&#x003b4;TCR (<xref ref-type="supplementary-material" rid="pone.0005926.s002">Figure S2B</xref>). By contrast, monocytes did neither express CD3 nor &#x003b3;&#x003b4;TCR (<xref ref-type="supplementary-material" rid="pone.0005926.s002">Figure S2C</xref>). Finally, neutrophils neither expressed CD3, &#x003b3;&#x003b4;TCR nor the full &#x003b1;&#x003b2;TCR complex at their surface (<xref ref-type="supplementary-material" rid="pone.0005926.s002">Figure S2D</xref>). Thus, following overnight culture, a fraction of eosinophils, unambiguously identified by the presence of specific eosinophil markers, express the &#x003b3;&#x003b4;TCR/CD3 complex at their surface.</p><p>Besides receptor reexpression at the membrane following a resting period, as demonstrated for NKG2A on &#x003b3;&#x003b4;T cells <xref ref-type="bibr" rid="pone.0005926-Boullier1">&#x0005b;35&#x0005d;</xref>, ligand-dependent induction or upregulation of receptor surface expression has been widely reported, including in the case of Fc&#x003b5;RI <xref ref-type="bibr" rid="pone.0005926-Kayaba1">&#x0005b;9&#x0005d;</xref>. Thus, we investigated whether a specific &#x003b3;&#x003b4;TCR ligand was able to induce &#x003b3;&#x003b4;TCR/CD3 surface expression on human eosinophils. While CD3 and &#x003b3;&#x003b4;TCR were barely detected at the surface of freshly purified eosinophils (<xref ref-type="supplementary-material" rid="pone.0005926.s003">Figure S3A</xref>), upon incubation for 2 h with TUBag1, a natural non peptidic ligand from <italic>Mycobacterium tuberculosis</italic><xref ref-type="bibr" rid="pone.0005926-Constant1">&#x0005b;36&#x0005d;</xref>, about 50&#x00025; of eosinophils expressed CD3 and &#x003b3;&#x003b4;TCR at their surface (<xref ref-type="supplementary-material" rid="pone.0005926.s003">Figure S3B</xref>). By contrast, neither CD8 nor &#x003b1;&#x003b2;TCR expression was induced upon incubation with TUBag (<xref ref-type="supplementary-material" rid="pone.0005926.s003">Figure S3B</xref>).</p><p>Finally, besides mature eosinophils present in peripheral blood, eosinophils can be differentiated <italic>in vitro</italic> from CD34<sup>&#x0002b;</sup> cord blood progenitors. In such EPO<sup>&#x0002b;</sup> eosinophils, in the absence of possible contamination by &#x003b3;&#x003b4;T cells, &#x003b3;&#x003b4;TCR/CD3 complex was detected at cell surface, after 3 weeks differentiation (<xref ref-type="supplementary-material" rid="pone.0005926.s004">Figure S4</xref>). As for blood eosinophils, neither CD8 nor &#x003b1;&#x003b2;TCR (not shown) could be detected.</p></sec><sec id="s2b"><title>Eosinophils express all the subunits from &#x003b3;&#x003b4;TCR/CD3 complex</title><p>To evidence the cellular distribution of &#x003b3;&#x003b4;TCR/CD3 complex and to further exclude that results obtained by flow cytometry could be due to contaminating &#x003b3;&#x003b4;T cells, blood eosinophils were analysed at low magnification by immunofluorescence and at high magnification by confocal microscopy. In full agreement with flow cytometry data, in a preparation without contaminating cells, only a fraction of blood eosinophils, identified by their typical binucleated morphology, expressed the four chains of CD3 and &#x003b3;&#x003b4;TCR. No signal was detected with anti-&#x003b1;TCR, anti-&#x003b2;TCR antibodies or control IgG (<xref ref-type="fig" rid="pone-0005926-g004">Fig 4A</xref>). We next characterized the structure of the &#x003b3;&#x003b4;TCR/CD3 complex expressed at the surface of eosinophils, using surface biotinylation, followed by lysis with a mild detergent, co-immunoprecipitation with an anti-&#x003b3;&#x003b4;TCR antibody, SDS-PAGE in reducing conditions and detection of biotinylated proteins. Bands corresponding to TCR, CD3&#x003b4;, &#x003b5;, &#x003b3; and &#x003b6; subunits were detected at the expected molecular weights both on &#x003b3;&#x003b4;T cells and eosinophils (<xref ref-type="fig" rid="pone-0005926-g004">Figure 4B</xref>). This result indicates that all the necessary chains are present to allow for surface expression of a complete &#x003b3;&#x003b4;TCR/CD3. However, the amount of material used for eosinophils was 10 times higher than for &#x003b3;&#x003b4;T cells, results consistent with flow cytometry data showing much lower surface expression in eosinophils than in &#x003b3;&#x003b4;T cells (<xref ref-type="fig" rid="pone-0005926-g002">Figure 2</xref> and <xref ref-type="supplementary-material" rid="pone.0005926.s002">Figure S2</xref>).</p><fig id="pone-0005926-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005926.g004</object-id><label>Figure 4</label><caption><title>Immunolocalization and Subunit composition of surface-expressed &#x003b3;&#x003b4;TCR/CD3 complex on human eosinophils.</title><p>(A) Immunofluorescence and confocal microscopy (insets) analysis of &#x003b3;&#x003b4;TCR/CD3 chains expression on cytospin eosinophil preparations after 18 h culture. Staining with anti-&#x003b1;TCR, anti-&#x003b2;TCR antibodies and control goat IgG is represented. Arrowheads indicate some positive cells. (B) Surface of eosinophils and &#x003b3;&#x003b4;T cells was biotin-labelled. Cells were lysed and complexes were immunoprecipitated, using anti-&#x003b3;&#x003b4;TCR or isotype control antibodies. Immunoprecipitated proteins were resolved on a reducing 14&#x00025; SDS-PAGE and transferred to PVDF membrane. Biotinylated proteins were revealed using ABC-HRP and chemiluminescence. Positions of the TCR and CD3 subunits are marked. Material corresponding to the total and to 1/10<sup>th</sup> of the material was loaded for eosinophils and &#x003b3;&#x003b4;T cells respectively. Dashed lines indicate that non adjacent lanes of the same gel have been joined on the Figure.</p></caption><graphic xlink:href="pone.0005926.g004"/></fig></sec><sec id="s2c"><title>&#x003b3;&#x003b4;TCR/CD3 is less abundant and more restricted in eosinophils than in &#x003b3;&#x003b4;T cells</title><p>Transcripts specific for the four chains (&#x003b5;, &#x003b6;, &#x003b3; and &#x003b4;) of CD3 complex, &#x003b3;TCR and &#x003b4;TCR constant regions and CD8 were amplified and quantified by real-time PCR in eosinophils purified to homogeneity (100&#x00025;) and &#x003b3;&#x003b4;T lymphocyte subsets or Colo-205 colon carcinoma cells as positive and negative controls respectively. Expression of the various chains was 300 to 4,000 fold lower in eosinophil population than in &#x003b3;&#x003b4;T lymphocyte population, while CD8 expression was absent in eosinophils but present in &#x003b3;&#x003b4;T lymphocytes (<xref ref-type="fig" rid="pone-0005926-g005">Figure 5A</xref>). Amplification of V&#x003b4;1-J&#x003b4;3, V&#x003b4;2-C&#x003b4; and V&#x003b3;I-J&#x003b3;P rearranged transcripts but not V&#x003b4;1-J&#x003b4;4 was also detected in eosinophils. These rearrangements were all found in &#x003b3;&#x003b4;T lymphocytes but neither in &#x003b1;&#x003b2;T lymphocytes nor Colo-205 cells (<xref ref-type="fig" rid="pone-0005926-g005">Figure 5B</xref>). Spectratyping analysis of CDR3 length profiles for V&#x003b3;9-J&#x003b3;1/2, V&#x003b3;9-J&#x003b3;P and V&#x003b4;2-C&#x003b4; evidenced a limited V&#x003b4;2-C&#x003b4; diversity (2 peaks) on eosinophils compared to &#x003b3;&#x003b4;T cells (<xref ref-type="fig" rid="pone-0005926-g005">Figure 5C</xref>), while no signal was detected on eosinophils for the 2 other rearrangements, in contrast to &#x003b3;&#x003b4;T cells (data not shown). Furthermore, to unambiguously demonstrate that TCR rearrangements occur in eosinophils, at single cell level, we performed <italic>in situ</italic> hybridization using sequences from rearranged TCR genes as RNA probes. Hybridization with anti-sense probes corresponding to V&#x003b4;2-C&#x003b4; and V&#x003b3;I-J&#x003b3;P rearrangements, that were detected by RT-PCR, gave a positive signal on nuclei from eosinophils at times clearly bilobed. In keeping with RT-PCR results, a significantly stronger signal was detected on &#x003b3;&#x003b4; T lymphocytes, while corresponding sense probes only gave background amplification on both cell types (<xref ref-type="fig" rid="pone-0005926-g005">Fig. 5D</xref>). V&#x003b4;1-J&#x003b4;4 anti-sense probe gave positive signal on &#x003b3;&#x003b4; T lymphocytes but not on eosinophils in which this rearrangement was not detected by RT-PCR.</p><fig id="pone-0005926-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005926.g005</object-id><label>Figure 5</label><caption><title>&#x003b3;&#x003b4;TCR/CD3 complex expression and rearrangements in human peripheral blood eosinophils.</title><p>(A) Real time PCR analysis of expression of individual chains from &#x003b3;&#x003b4;TCR/CD3 complex in eosinophils, &#x003b3;&#x003b4; T cells and Colo-205 cells. Average expression in Colo-205 cells is chosen as reference (samples were analysed in triplicate using primers listed in <xref ref-type="supplementary-material" rid="pone.0005926.s005">Table S1</xref>). (B) TCR&#x003b3; and &#x003b4; rearrangements in peripheral blood eosinophils analysed by RT-PCR using primers listed in <xref ref-type="supplementary-material" rid="pone.0005926.s006">Table S2</xref>. CD8 amplification is performed to exclude lymphocyte contamination. Colo-205 are chosen as negative control (C) Spectratyping analysis of CDR3 length profiles for V&#x003b3;9-J&#x003b3;1/2 ; V&#x003b3;9-J&#x003b3;P and V&#x003b4;2-C&#x003b4; families in eosinophils and in &#x003b3;&#x003b4; T cells from the same donor. (D) Expression of rearranged &#x003b3; and &#x003b4;TCR at the single cell level in peripheral blood eosinophils and &#x003b3;&#x003b4;T cells detected by <italic>in situ</italic> hybridization using anti-sense and control sense probes specific for V&#x003b4;2-C&#x003b4;, V&#x003b3;I-J&#x003b3;P and for V&#x003b4;1-J&#x003b4;4 used as negative control.</p></caption><graphic xlink:href="pone.0005926.g005"/></fig><p>Finally, DNA sequencing of V&#x003b4;1J&#x003b4;3 V&#x003b4;2-C&#x003b4; regions from eosinophils and &#x003b3;&#x003b4;T cells show that V and J regions were virtually identical to the IMGT sequence, while significant differences between eosinophils and 2 different cloned sequences of &#x003b3;&#x003b4;T cells from the same donor were found in D regions and in junctional regions (<xref ref-type="fig" rid="pone-0005926-g006">Figure 6</xref>). This further confirms that &#x003b3;&#x003b4;TCR/CD3 complex expressed by eosinophils is less expressed and diverse than the corresponding receptor on &#x003b3;&#x003b4; T cells.</p><fig id="pone-0005926-g006" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005926.g006</object-id><label>Figure 6</label><caption><title>Intraindividual variability between eosinophils and &#x003b3;&#x003b4;T cells in rearranged V&#x003b4;1-J&#x003b4;3 and V&#x003b4;2-C&#x003b4; TCR sequences.</title><p>(A) TCR locus organization with positions of the PCR probes used for sequence amplification. (B&#x02013;C) Sequence alignment of V&#x003b4;1-J&#x003b4;3 (B) and V&#x003b4;2-C&#x003b4; (C) regions analyzed from IGMT database, differentiated &#x003b3;&#x003b4;T cells and peripheral blood eosinophils obtained from the same allergic donors for. The two most frequent sequences are presented for &#x003b3;&#x003b4;T cells. Grey boxes indicate mismatch.</p></caption><graphic xlink:href="pone.0005926.g006"/></fig></sec><sec id="s2d"><title>&#x003b3;&#x003b4;TCR/CD3-mediated eosinophil activation induces ROS production, degranulation and cytokine release</title><p>Upon activation, eosinophils very rapidly produce Reactive Oxygen Species (ROS) and release, by selective degranulation, eosinophil-specific granule proteins, including highly cytotoxic cationic proteins such as EPO and eosinophil cationic protein (ECP) <xref ref-type="bibr" rid="pone.0005926-Gounni1">&#x0005b;6&#x0005d;</xref>. In purified blood eosinophils, &#x003b3;&#x003b4;TCR/CD3 complex activation by immobilized antibodies to CD3, &#x003b3;&#x003b4;TCR or V&#x003b4;1 led to a similar kinetics of ROS production (<xref ref-type="fig" rid="pone-0005926-g007">Figure 7A</xref>) and to a significant EPO and eosinophil-derived neurotoxin (EDN) release (<xref ref-type="fig" rid="pone-0005926-g007">Figure 7D and G</xref>). Stimulation with a soluble ligand, bromohydrin pyrophosphate (BrHPP), a phosphoantigen agonist selective for human &#x003b3;9&#x003b4;2<sup>&#x0002b;</sup> T lymphocytes <xref ref-type="bibr" rid="pone.0005926-Espinosa1">&#x0005b;37&#x0005d;</xref>, induced dose-dependent ROS production as well as EPO release (<xref ref-type="fig" rid="pone-0005926-g007">Figure 7B and E</xref>). Furthermore, eosinophil activation by sec-butylamine (SBA) <xref ref-type="bibr" rid="pone.0005926-Thompson1">&#x0005b;38&#x0005d;</xref>, an inducer of endogenous phosphoantigens, yielded to a sustained dose-dependent ROS and EPO production (<xref ref-type="fig" rid="pone-0005926-g007">Figure 7C and F</xref>), comparable to values obtained following activation with IgA/anti-IgA immune complexes, one potent physiological eosinophil activator. Of note, plate-bound antibodies induced stronger ROS release but weaker EPO release than soluble &#x003b3;&#x003b4;TCR activators. Since eosinophils also release several immuno-regulatory and proinflammatory cytokines <xref ref-type="bibr" rid="pone.0005926-Woerly1">&#x0005b;10&#x0005d;</xref>, we further show that activation with anti-CD3, -&#x003b3;&#x003b4;TCR or -V&#x003b4;1 antibodies efficiently induced IFN-&#x003b3; and TNF-&#x003b1; production by eosinophils (<xref ref-type="fig" rid="pone-0005926-g007">Figure 7H and I</xref>). Thus, &#x003b3;&#x003b4;TCR/CD3-expressing eosinophils respond to selective agonists similarly to human &#x003b3;&#x003b4;T lymphocytes and produce both specific eosinophil granule proteins, myeloid cell mediators as well as cytokines.</p><fig id="pone-0005926-g007" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005926.g007</object-id><label>Figure 7</label><caption><title>Specific mediator release upon CD3- or &#x003b3;&#x003b4;TCR-induced eosinophil activation.</title><p>(A&#x02013;C) Representative time course of ROS production following eosinophil activation by immunobilized specific antibodies (A), BrHPP (B) or SBA stimulation (C). (A) Stimulation with immobilized anti-CD3 (&#x025aa;), anti-&#x003b3;&#x003b4;TCR (X) or anti-V&#x003b4;1 (&#x025b4;) mAbs or control IgG<sub>1</sub> (&#x02666;). (B) Stimulation by BrHPP 200 nM (&#x025cb;) 100 nM (&#x025aa;) and 50 nM (&#x025ca;) or culture medium (&#x02666;). (C) Stimulation by SBA 500 &#x000b5;M (&#x025a1;) 50 &#x000b5;M (&#x025b4;) and 5 &#x000b5;M (X), culture medium (&#x02666;) or IgA/anti-IgA immune complexes (&#x02022;). (D&#x02013;F) EPO release by eosinophils upon CD3 or &#x003b3;&#x003b4;TCR activation by specific antibodies (D) (n&#x0200a;&#x0003d;&#x0200a;6), BrHPP (E) (n&#x0200a;&#x0003d;&#x0200a;3) or SBA stimulation (F) (n&#x0200a;&#x0003d;&#x0200a;3). Results are expressed in count per second (cps). (G) EDN release by eosinophils upon CD3 or &#x003b3;&#x003b4;TCR activation by specific antibodies (n&#x0200a;&#x0003d;&#x0200a;6). (H&#x02013;I) Cytokine production by eosinophils upon CD3 or &#x003b3;&#x003b4;TCR activation by specific antibodies or IgA/anti-IgA immune complexes. IFN-&#x003b3; production (H) (n&#x0200a;&#x0003d;&#x0200a;5&#x02013;7) and TNF-&#x003b1; production (I) (n&#x0200a;&#x0003d;&#x0200a;4&#x02013;8). Results presented in panels E and F were obtained on different patients. &#x0002a;, P&#x0003c;0.05; &#x0002a;&#x0002a;, P&#x0003c;0.01.</p></caption><graphic xlink:href="pone.0005926.g007"/></fig></sec><sec id="s2e"><title><italic>Mycobacterium bovis</italic> induce &#x003b3;&#x003b4;TCR/CD3-dependent eosinophil activation</title><p>Human &#x003b3;&#x003b4;T cells respond to non-peptide antigens including mycobacterial and tumor-derived ligands. Patients with mycobacterial infections may exhibit blood and tissue eosinophilia and mycobacteria-induced eosinophil-associated experimental acute inflammation <xref ref-type="bibr" rid="pone.0005926-Lasco1">&#x0005b;39&#x0005d;</xref> as well as rapid eosinophil chemotaxis <italic>in vivo</italic>. Mycobacteria- eosinophil interactions might thus reflect the reactivity conferred by &#x003b3;&#x003b4;TCR/CD3 complex. Accordingly, incubation of blood eosinophils with increasing ratios of <italic>Mycobacterium bovis</italic>-BCG induced dose-dependent ROS production and EPO release (<xref ref-type="fig" rid="pone-0005926-g008">Figure 8A&#x02013;B</xref>), that could be inhibited, in a dose-dependent manner, by an anti-&#x003b3;&#x003b4;TCR antibody <xref ref-type="bibr" rid="pone.0005926-Groh1">&#x0005b;40&#x0005d;</xref> (<xref ref-type="fig" rid="pone-0005926-g008">Figure 8C&#x02013;D</xref>). Similar eosinophil activation, and inhibition by an anti-&#x003b3;&#x003b4;TCR antibody, was also obtained following incubation with TUBag, a natural mycobacterial component (<xref ref-type="fig" rid="pone-0005926-g008">Figure 8E&#x02013;H</xref>). Thus mycobacteria appear capable of activating eosinophils, at least partly, in a &#x003b3;&#x003b4;TCR-dependent manner.</p><fig id="pone-0005926-g008" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005926.g008</object-id><label>Figure 8</label><caption><title><italic>Mycobacterium bovis</italic>-BCG-induced eosinophil activation.</title><p>(A and E) Dose-dependent ROS production by BCG- (A) or TUBag (E) activated eosinophils. BCG/eosinophil ratio: 20/1 (&#x02022;), 10/1 (&#x025ca;), 5/1 (&#x0002b;) and 0/1 (&#x02212;). (B and F) Dose-dependent EPO release by eosinophils activated by different BCG/eosinophil ratios (n&#x0200a;&#x0003d;&#x0200a;3) (B) or TUBag concentrations (F). (C and G) Inhibition of BCG- (ratio 20/1 &#x02022;) (C) or TUBag- (G) induced ROS production by an anti-&#x003b3;&#x003b4;TCR blocking antibody 5 &#x000b5;g/ml (x) and 10 &#x000b5;g/ml (&#x025cb;) or an isotype control antibody (&#x00394;). (D and G) Inhibition of BCG- (D) or TUBag- (G) induced EPO production by an anti-&#x003b3;&#x003b4;TCR blocking antibody (5 and 10 &#x000b5;g/ml) or an isotype control antibody. Results are expressed as &#x00394;EPO cps values (values from medium stimulation are subtracted from values obtained with BCG stimulation for each antibody) (n&#x0200a;&#x0003d;&#x0200a;3). (E&#x02013;F) &#x0002a;, P&#x0003c;0.05; &#x0002a;&#x0002a;, P&#x0003c;0.01.</p></caption><graphic xlink:href="pone.0005926.g008"/></fig></sec><sec id="s2f"><title>&#x003b3;&#x003b4;TCR/CD3-dependent eosinophil cytotoxicity toward tumor cells</title><p>Eosinophils have been associated with many tumors <italic>in vivo</italic>. Furthermore, both &#x003b3;&#x003b4; T cells <xref ref-type="bibr" rid="pone.0005926-Hayday2">&#x0005b;41&#x0005d;</xref> and eosinophils <xref ref-type="bibr" rid="pone.0005926-Munitz1">&#x0005b;19&#x0005d;</xref> exert potent cytotoxic activity towards many tumor cells. Therefore, we investigated &#x003b3;&#x003b4;TCR-mediated eosinophil cytotoxicity towards Colo-205 carcinoma cell line. Indeed, eosinophils induced time-dependent apoptosis of Colo-205 tumor cells <italic>in vitro</italic>, which was significantly inhibited following addition of neutralizing anti-&#x003b3;&#x003b4;TCR Ab (<xref ref-type="fig" rid="pone-0005926-g009">Figure 9A</xref>). This effect was more prominent at earlier time-points suggesting that &#x003b3;&#x003b4;TCR-mediated eosinophil-tumor interactions are important for the initiation of the cytotoxic reaction (<xref ref-type="fig" rid="pone-0005926-g009">Figure 9B</xref>). Finally preincubation of eosinophils with &#x003b3;&#x003b4;TCR ligands, SBA and TUBag, potentiated eosinophil cytotoxicity towards tumor cells (<xref ref-type="fig" rid="pone-0005926-g009">Figure 9C&#x02013;D</xref>). Altogether, these data confirm the potential role of eosinophils in anti-tumor cytotoxicity and strongly suggest the involvement of &#x003b3;&#x003b4;TCR/CD3 complex in this mechanism.</p><fig id="pone-0005926-g009" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005926.g009</object-id><label>Figure 9</label><caption><title>&#x003b3;&#x003b4;TCR-dependent tumor-cell killing by human eosinophils.</title><p>(A&#x02013;B) Induction of Colo205 killing by eosinophils and inhibition by an anti-&#x003b3;&#x003b4;TCR blocking antibody. Percentage of AnnexinV<sup>&#x0002b;</sup> tumor cells in the presence or absence of eosinophils and blocking anti-&#x003b3;&#x003b4;TCR or isotype control antibodies (n&#x0200a;&#x0003d;&#x0200a;5&#x02013;7) at various time-points. Panel A represents the 60 min time-point. (C&#x02013;D) Potentiation of eosinophil-mediated Colo205 killing by &#x003b3;&#x003b4;TCR ligands. (C) 50 &#x000b5;M SBA (n&#x0200a;&#x0003d;&#x0200a;7). (D) 20 mM TUBag (n&#x0200a;&#x0003d;&#x0200a;4). &#x0002a;, P&#x0003c;0.05; &#x0002a;&#x0002a;, P&#x0003c;0.01.</p></caption><graphic xlink:href="pone.0005926.g009"/></fig></sec></sec><sec id="s3"><title>Discussion</title><p>We here provide evidence that highly purified human blood eosinophils, as well as eosinophils differentiated <italic>in vitro</italic> from CD34<sup>&#x0002b;</sup> cord blood progenitors, gated on the basis of presence of specific eosinophil granule proteins, express a functional &#x003b3;&#x003b4;TCR/CD3 complex, so far almost exclusively associated to T lymphocytes, but lack &#x003b1;&#x003b2;TCR. As previously observed for other receptors such as CD25 <xref ref-type="bibr" rid="pone.0005926-Rand1">&#x0005b;42&#x0005d;</xref>, CD4 <xref ref-type="bibr" rid="pone.0005926-Lucey2">&#x0005b;18&#x0005d;</xref>, Fc&#x003b5;RI, CD89 and CD28 <xref ref-type="bibr" rid="pone.0005926-Woerly1">&#x0005b;10&#x0005d;</xref>, &#x003b3;&#x003b4;TCR/CD3 surface expression on eosinophils is highly heterogeneous between individual donors. Such an heterogeneity in &#x003b3;&#x003b4;TCR/CD3 expression has also been observed for human blood &#x003b3;&#x003b4;T lymphocytes <xref ref-type="bibr" rid="pone.0005926-Boullier1">&#x0005b;35&#x0005d;</xref>. As it is the case for several receptors, including Fc&#x003b5;RI <xref ref-type="bibr" rid="pone.0005926-Kayaba1">&#x0005b;9&#x0005d;</xref>, surface expression of &#x003b3;&#x003b4;TCR/CD3 can be induced/up-regulated, in particular upon incubation with ligands. Our results show that &#x003b3;&#x003b4;TCR surface expression was induced upon incubation in the presence of a natural mycobacterial ligand as well as following overnight culture. The molecular mechanism underlying this later finding remains unknown. Our results indicate that CD3&#x003b5; expression, both at mRNA and protein levels, was consistently lower than &#x003b3;&#x003b4;TCR. Due to the requirement of this CD3 subunit for surface expression of the receptor complex, it is tempting to speculate that the very low CD3&#x003b5; expression probably accounts for the low surface expression of the whole complex on eosinophils although further experiments would be required for a formal demonstration. This low receptor expression as well as the fragility of eosinophils was a constraint to obtain significant amounts of viable &#x003b3;&#x003b4;TCR<sup>&#x0002b;</sup> eosinophils following cell sorting.</p><p>Eosinophils display a rearranged &#x003b3;&#x003b4;TCR with a more restricted repertoire compared to &#x003b3;&#x003b4;T cells, further excluding the possibility of lymphocyte contaminants in eosinophil preparations. Besides T lymphocytes, &#x003b4;TCR rearrangements have only been reported in malignant B lymphoblasts <xref ref-type="bibr" rid="pone.0005926-Krejci1">&#x0005b;43&#x0005d;</xref>, NK cells <xref ref-type="bibr" rid="pone.0005926-Fronkova1">&#x0005b;44&#x0005d;</xref> and in mixed-type leukaemia retaining both T-lymphoid and myeloid characteristics. Furthermore, presence of double positive V&#x003b4;1<sup>&#x0002b;</sup>V&#x003b4;2<sup>&#x0002b;</sup> and equal numbers of V&#x003b4;1- and V&#x003b4;2-expressing eosinophils in most of normal donors suggests incomplete allelic exclusion as found in some instances in &#x003b3;&#x003b4;T cells <xref ref-type="bibr" rid="pone.0005926-Couedel1">&#x0005b;45&#x0005d;</xref>. Direct &#x003b3;&#x003b4;TCR activation of eosinophils by &#x003b3;&#x003b4;TCR/CD3-specific antibodies and selective agonists induced eosinophil-specific responses. Release of such myeloid-associated mediators and the scarcity of circulating &#x003b3;&#x003b4; T cells further exclude the possibility that our results obtained using highly purified eosinophils would be due to &#x003b3;&#x003b4;TCR expression by contaminating lymphocytes.</p><p>Thus, mature eosinophils expressing lymphoid markers might represent hitherto unattended &#x003b3;&#x003b4;TCR-expressing myeloid cells. Our results might be in agreement with observations that myeloid-derived plasmacytoid DC are able to express a &#x0201c;lymphoid program&#x0201d; (RAG1, rearranged IgH genes) <xref ref-type="bibr" rid="pone.0005926-Shigematsu1">&#x0005b;46&#x0005d;</xref>. By contrast, in the recently proposed myeloid-based model of haematopoiesis, T- or B-committed progenitors would each keep a myeloid-differentiation potential <xref ref-type="bibr" rid="pone.0005926-Kawamoto1">&#x0005b;47&#x0005d;</xref>. For instance, genetic reprogramming from differentiated B cells to macrophages has been reported <xref ref-type="bibr" rid="pone.0005926-Xie1">&#x0005b;48&#x0005d;</xref>. Further experiments are required to unravel by which mechanisms eosinophils have acquired this lymphoid program. Of note, eosinophils are found in human thymus <xref ref-type="bibr" rid="pone.0005926-Jacobsen2">&#x0005b;8&#x0005d;</xref>. Furthermore, similarly to gut intraepithelial &#x003b3;&#x003b4;T cells, eosinophils are able to undergo peripheral differentiation, for instance in allergic lungs <xref ref-type="bibr" rid="pone.0005926-Sehmi1">&#x0005b;49&#x0005d;</xref>. Investigating TCR expression by eosinophils in various organs and tissues would greatly benefit from experiments on animal models. Unfortunately, we were unable to detect &#x003b3;&#x003b4;TCR/CD3 on mouse blood and tissue eosinophils. This is not extremely surprising since mouse eosinophils are strikingly different from human eosinophils, regarding their granular content <xref ref-type="bibr" rid="pone.0005926-Lee1">&#x0005b;50&#x0005d;</xref> and membrane expression of various immune receptors, in particular IgE receptors <xref ref-type="bibr" rid="pone.0005926-deAndres1">&#x0005b;51&#x0005d;</xref> and IgA receptors <xref ref-type="bibr" rid="pone.0005926-Decot1">&#x0005b;52&#x0005d;</xref>. Furthermore, &#x003b3;&#x003b4;T cells also display significant differences between mouse and humans. Indeed, a high proportion of skin lymphocytes express &#x003b3;&#x003b4;TCR in mouse but not in human <xref ref-type="bibr" rid="pone.0005926-Jameson1">&#x0005b;53&#x0005d;</xref>, while only human V&#x003b3;9V&#x003b4;2 are responsive to phosphoantigens <xref ref-type="bibr" rid="pone.0005926-OBrien1">&#x0005b;54&#x0005d;</xref>.</p><p>Our findings indicate that eosinophils might also contribute, through &#x003b3;&#x003b4;TCR-dependent mechanisms, to immune defences in tissues, where 90&#x00025; eosinophils are located. One might speculate that &#x003b3;&#x003b4;TCR/CD3 expression is higher in tissue than in blood eosinophils, as previously reported for Fc&#x003b5;RI in a model of &#x0201c;humanized&#x0201d; mice where human Fc&#x003b5;RI was quantified and increasingly expressed from blood to peritoneal cavity and spleen eosinophils <xref ref-type="bibr" rid="pone.0005926-Kayaba1">&#x0005b;9&#x0005d;</xref>. Tissue eosinophils are associated to granulomatous diseases such schistosomiasis <xref ref-type="bibr" rid="pone.0005926-Hsu1">&#x0005b;55&#x0005d;</xref>, Crohn's disease <xref ref-type="bibr" rid="pone.0005926-Choy1">&#x0005b;56&#x0005d;</xref> and mycobacterial infections <xref ref-type="bibr" rid="pone.0005926-Lasco1">&#x0005b;39&#x0005d;</xref>. Eosinophils can damage cell wall and lyse <italic>Mycobacterium tuberculosis in vitro</italic><xref ref-type="bibr" rid="pone.0005926-Borelli1">&#x0005b;57&#x0005d;</xref>. V&#x003b3;9&#x003b4;2 and V&#x003b4;1 expression, rapid response to phosphoantigen ligands, as well as BCG-induced activation so far represented hallmarks of &#x003b3;&#x003b4;T lymphocyte-mediated cytotoxicity towards phosphoantigen-expressing mycobacteria <xref ref-type="bibr" rid="pone.0005926-Thedrez1">&#x0005b;58&#x0005d;</xref>. Since tumors produce phosphoantigens and are targeted by &#x003b3;&#x003b4;T lymphocytes <xref ref-type="bibr" rid="pone.0005926-Thedrez1">&#x0005b;58&#x0005d;</xref>, &#x003b3;&#x003b4;TCR-mediated activation might thus contribute to the anti-tumoral activity of eosinophils. Indeed, while &#x003b3;&#x003b4;T lymphocytes and NK cells display granzyme B/perforin-mediated cytotoxicity, eosinophils additionally possess a unique set of cationic proteins with a strong cytotoxic potential <xref ref-type="bibr" rid="pone.0005926-Lee1">&#x0005b;50&#x0005d;</xref>. Furthermore, tumor-associated tissue eosinophilia (TATE) is considered by some authors as a marker of good prognosis, including in colon carcinoma <xref ref-type="bibr" rid="pone.0005926-FernandezAcenero1">&#x0005b;59&#x0005d;</xref>. Anti-tumoral activity of eosinophils should be considered in the context of current development of innovative cancer immunotherapies, based on synthetic phosphoantigens <xref ref-type="bibr" rid="pone.0005926-Bennouna1">&#x0005b;60&#x0005d;</xref>. Indeed, due to their high cytotoxic potential and despite their low &#x003b3;&#x003b4;TCR expression in comparison to T cells, eosinophils might thus represent very efficient &#x0201c;innate&#x0201d; effector cells in defence against targets bearing &#x003b3;&#x003b4;TCR ligands, such as tumor cells, in particular when eosinophils surround or infiltrate solid tumors.</p><p>Our work outlines a previously unexpected link between eosinophils and &#x003b3;&#x003b4;T lymphocytes, which not only share the expression of the &#x003b3;&#x003b4;TCR/CD3 complex but also some major functions in innate immunity. It might also shed light on the molecular mechanisms of differentiation, diversity and function of T-cell expressed &#x003b3;&#x003b4;TCR.</p></sec><sec sec-type="materials|methods" id="s4"><title>Materials and Methods</title><sec id="s4a"><title>Ethics statement</title><p>Peripheral venous blood was obtained from healthy donors or eosinophilic patients after written informed consent. Research protocol was approved by the Comit&#x000e9; Consultatif de Protection des Personnes dans la Recherche Biom&#x000e9;dicale de Lille (France).</p></sec><sec id="s4b"><title>Cell purification and culture</title><p>Eosinophils were isolated as described <xref ref-type="bibr" rid="pone.0005926-Legrand1">&#x0005b;61&#x0005d;</xref> on Percoll followed by negative selection using anti-CD16-coated microbeads. Purity determined after cytospin and RAL555 staining was above 98&#x00025; and 100&#x00025; for RNA analyses. Purified eosinophils were cultured overnight at 37&#x000b0;C in complete RPMI without phenol red.</p><p>Neutrophils were obtained by positive selection with anti-CD16 coated microbeads. Purity was 99&#x00025;. For RNA extraction, &#x003b1;&#x003b2;TCR lymphocytes from PBMC from normal donors were sorted after staining with anti-&#x003b1;&#x003b2;TCR-PE using FacsAria&#x02122; cell sorter and Diva&#x02122; software (BD). Purity was 99&#x00025;. &#x003b3;&#x003b4;TCR lymphocytes were generated from PBMC (0.5&#x000d7;10<sup>6</sup>/ml) by culture in complete RPMI 1640 medium with 200 nM bromohydrin pyrophosphate BrHPP (Innate Pharma, Marseille) and 20 ng/ml rhIL-2 for 7 days. At that time, 50&#x02013;70&#x00025; cells were &#x003b3;9&#x003b4;2TCR<sup>&#x0002b;</sup> cells. For RT-PCR and <italic>in situ</italic> hybridization, &#x003b3;&#x003b4;TCR<sup>&#x0002b;</sup> cells were further purified using anti-&#x003b3;&#x003b4;TCR microbeads (Miltenyi).</p><p>Cord blood was obtained from the maternity unit of Lille University Hospital. Mononuclear cells were isolated by Ficoll-Hypaque density centrifugation. CD34<sup>&#x0002b;</sup> cells were purified using CD34<sup>&#x0002b;</sup> isolation kit (Miltenyi). Purified CD34<sup>&#x0002b;</sup> cells were cultured in complete medium supplemented with 2.5&#x000d7;10<sup>&#x02212;5</sup> M &#x003b2;-mercaptoethanol (&#x003b2;-ME) at 0.5&#x000d7;10<sup>6</sup> cells/ml. Eosinophil differentiation was induced upon addition of 50 ng/ml SCF, 1 ng/ml each GM-CSF, IL-3 and IL-5 (Peprotech).</p><p>Colo-205 colon carcinoma cell line was obtained from ATCC. Cells were maintained in RPMI 1640 medium supplemented with 10&#x00025; FCS, 10 mM L-Glutamine and 10 &#x000b5;g/ml Gentamycin.</p></sec><sec id="s4c"><title>Flow cytometry</title><p>Antibodies and isotype controls used for flow cytometry (origin, clone, working dilution or concentration) are listed in <xref ref-type="supplementary-material" rid="pone.0005926.s005">Table S1</xref>. Anti-EPO (AHE) and anti-MBP2 <xref ref-type="bibr" rid="pone.0005926-Plager1">&#x0005b;62&#x0005d;</xref> (a kind gift from Dr. D Plager, Mayo Clinic, Rochester) were biotinylated using biotin-sulfosuccinimidyl ester (Molecular Probes) according to manufacturer's instructions and used at a 1&#x02236;100 dilution. Samples were analysed on a FACSCalibur&#x02122; using CellQuest&#x02122; software (BD). Multiple staining experiments are represented as color density plots <xref ref-type="bibr" rid="pone.0005926-Herzenberg1">&#x0005b;63&#x0005d;</xref> with linear scales used for both forward (FSC) and side scatter (SSC) and logarithmic scales used for fluorescence parameters (Log density: 50&#x00025;).</p><p>Intracellular staining was performed after fixation of purified eosinophils, neutrophils or PBMC (2&#x000d7;10<sup>5</sup>) with 2&#x00025; paraformaldehyde and permeabilization with 0.01&#x00025; saponin in PBS. After blocking of non-specific binding with 5 &#x000b5;l mouse serum for 10 min, cells were incubated with anti-CD3-FITC, anti-&#x003b1;&#x003b2;TCR-FITC, anti-&#x003b3;&#x003b4;TCR-FITC or anti-CD8-FITC or corresponding isotype controls for 30 min in the presence of saponin.</p><p>Following incubation for 2 h with or without TUBag-1 <xref ref-type="bibr" rid="pone.0005926-Constant1">&#x0005b;36&#x0005d;</xref> (40 nM) in RMPI 1640 or after overnight culture, purified blood eosinophils were gated prior to the analysis, on the basis of their FSC and SSC characteristics in order to exclude dead cells (<xref ref-type="fig" rid="pone-0005926-g001">Figure 1B</xref>). Within PBMC fraction, monocytes and lymphocytes were gated on the basis of their FSC and SSC characteristics prior to the analysis. Quadrants were set on samples after double staining with FITC- or APC- and PE- or biotin-conjugated control isotype antibodies. At least 10<sup>4</sup> events were acquired per sample.</p><p>For double and triple staining, cultured peripheral eosinophils were preincubated with 5&#x00025; human serum albumin (HSA) for 30 min at 4&#x000b0;C and labelled for membrane receptor with the relevant fluorochrome-conjugated antibodies. After washing, cells were fixed 10 min with 2&#x00025; paraformaldehyde at 4&#x000b0;C and permeabilized for 10 min at room temperature (RT) with 0.01&#x00025; saponin in PBS-1&#x00025; BSA. Non-specific binding was blocked with 5 &#x000b5;l mouse serum for 10 min. Purified peripheral blood eosinophils were further identified by incubation with biotinylated anti-EPO or anti-MBP or isotype control for 30 min and streptavidin-PE (Molecular Probes) (1&#x02236;200) for 20 min in the presence of saponin. Neutrophils were identified by intracellular staining with anti-MPO-PE following an identical procedure. Monocytes and T lymphocytes were identified by staining with anti-CD14-PE, anti-&#x003b1;&#x003b2;TCR or anti-&#x003b3;&#x003b4;TCR respectively.</p></sec><sec id="s4d"><title>Immunofluorescence and confocal microscopy</title><p>Purified eosinophils were cytocentrifuged, fixed in 4&#x00025; paraformaldehyde, washed in 0.05 M PBS. Fixation was stopped with 0.1 M glycine for 4 min and 50 mM NH<sub>4</sub>Cl pH 7.4 for 15 min. After each incubation step, cytospins were washed for 10 min in PBS. Cells were incubated with PBS-3&#x00025; BSA-5&#x00025; HSA for 30 min and, after one PBS wash, with 10&#x00025; decomplemented donkey serum (Jackson ImmunoResearch). Cytospins were then incubated overnight at 4&#x000b0;C in a humid chamber with goat antibodies specific for CD3&#x003b5;, CD3&#x003b6;, CD3&#x003b3;, CD3&#x003b4;, &#x003b1;TCR, &#x003b2;TCR, &#x003b3;TCR, &#x003b4;TCR (Santa Cruz) or with goat IgG (Jackson ImmunoResearch) in PBS-BSA-HSA (40 &#x000b5;g/ml). After washing in PBS-0.1&#x00025; BSA, cells were incubated with biotinylated donkey anti-goat IgG (Jackson ImmunoResearch) (1&#x02236;200) in PBS-BSA-HSA for 2 hours, followed by streptavidin-Texas Red (Molecular Probes) (1&#x02236;500) in PBS-3&#x00025; BSA for 1 hour. Final washes were with PBS-0.1&#x00025; BSA- 0.02&#x00025; Tween 20 for 2&#x000d7;10 min and with PBS for 10 min. For immunofluorescence, DNA was stained with Hoechst 33342 (Invitrogen) (1&#x02236;1000), immediately prior to cytospin mounting in Fluoromount G (Southern Biotechnologies).</p><p>For conventional immunofluorescence a Leica DM-RB microscope equipped for epifluorescence with a 100 W mercury lamp was used. Filter and dichroic mirror sets were TX2 for Texas Red and A for Hoechst 33342. Images were acquired with a 100&#x000d7;1.32 NA oil immersion objective, a Photometrics Cool SNAP&#x02122; camera using RSImage&#x02122; software (Roper Scientific). Samples were analysed by confocal microscopy using a DM-IRE2 inverted microscope with SP2-AOBS scan-head (Leica) at the Imaging Facility of Institut Pasteur de Lille. Excitation was performed at 543 nm for Texas Red. Fluorescence emission wavelengths pass bands were selected between 581 and 621 nm according to the emission spectral analysis. Excitation power was between 100 and 400 &#x000b5;W. Acquisitions were performed using a 100&#x000d7;1.4 NA oil immersion objective. 3D pre-treatment, analysis and edition were performed with Edit3D (free software, Y. Usson, GDR2588, CNRS, France). Analysis and editing was performed on Photoshop (Adobe).</p></sec><sec id="s4e"><title>Surface immunoprecipitation</title><p>Surface labelling and co-immunoprecipitation was performed as previously described for &#x003b3;&#x003b4; T cells <xref ref-type="bibr" rid="pone.0005926-Hayes1">&#x0005b;64&#x0005d;</xref>. Purified human eosinophils or differenciated &#x003b3;&#x003b4;T cells were washed and then resuspended in PBS (pH 8.0) at 3.10<sup>7</sup> cells/ml at room temperature. Surface biotinylation was performed for 30 min at room temperature using 2 mM Sulfo-NHS-LC-Biotin (Pierce Biotechnology). Cells were washed three times with PBS containing 100 nM glycine and once in PBS.</p><p>Labelled cells were lysed in a buffer containing 20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, protease inhibitors and 1&#x00025; Brij 97 (Sigma-Aldrich). Lysates were cleared by centrifugation for 15 min at 12,000 <italic>g</italic> and sequentially incubated at 4&#x000b0;C in the presence of Protein-G Sepharose (Gamma bind Plus Sepharose, Pharmacia), Protein G Sepharose-bound normal mouse IgG (Jackson Immunoresearch) and Protein G Sepharose-bound anti-&#x003b3;&#x003b4;TCR. Immunoprecipitated samples were washed three times with lysis buffer then boiled in reducing sample buffer (30 mM Tris, pH 6.8, 5&#x00025; glycerol, 2&#x00025; SDS, 2.5&#x00025; &#x003b2;-mercaptoethanol, 0.1&#x00025; bromophenol blue). Material was run on 14&#x00025; polyacrylamide gels. Material corresponding to the total and to 1/10<sup>th</sup> of the material was loaded for eosinophils and &#x003b3;&#x003b4;T cells respectively. Following separation, proteins were transferred to PVDF membrane (Biorad). Blots were developed using ABC-HRP (Vector Laboratories) and the enhanced chemiluminescence (ECL) plus Western blot detection system (Amersham).</p></sec><sec id="s4f"><title>PCR analysis</title><p>Total RNA was isolated using the RNeasy mini kit (Qiagen) from 10<sup>7</sup> purified cells and reverse transcription was performed using SuperScript&#x02122;RT (MMLV 200 U/&#x000b5;l) (Invitrogen). cDNA was amplified using primers (Proligo) (20 pmoles/&#x000b5;l) listed in <xref ref-type="supplementary-material" rid="pone.0005926.s006">Table S2</xref>. PCR were run for 40 cycles (1 min at 95&#x000b0;C, 1 min annealing and 1 min at 72&#x000b0;C) using Taq polymerase (Bioprobe).</p></sec><sec id="s4g"><title>Real time PCR</title><p>Total RNA was prepared from eosinophils by guanidium/CsCl centrifugation method. Briefly, purified eosinophils were pelleted by centrifugation and then lysed in 4 M guanidium isothiocyanate, 1 mM EDTA, 25 mM sodium acetate, 4.9&#x00025; &#x003b2;-mercaptoethanol, 68 mM N-lauryl sarcosine. Lysate was drawn through a 20G needle. RNA was obtained by ultracentrifugation (28000 rpm, 20 h, and 20&#x000b0;C) through a CsCl gradient. RNA pellet was washed twice and dissolved in water and precipitated overnight at &#x02212;20&#x000b0;C with ethanol 70&#x00025; and sodium acetate 0.08 M. After centrifugation (10000 rpm, 45 minutes at 4&#x000b0;C), RNA was washed twice in ethanol 70&#x00025;, resuspended in water and store at &#x02212;80&#x000b0;C until use. RNA from &#x003b3;&#x003b4; T cells and Colo205 cells was prepared using RNeasy mini-spin columns (Qiagen, UK) according to the manufacturer's instructions. All samples were quantified by absorbance measurement at 260 nm on a spectrophotometer (Biorad), and RNA quality was checked by running samples on 1.5&#x00025; agarose gel in RNA loading buffer (Sigma).</p><p>Total RNA was first submitted to DNAse I (Invitrogen) treatment (15 min at room temperature), and cDNA was generated using Superscript II reverse transcriptase (Invitrogen) according to the manufacturer instructions. Samples were analyzed by quantitative real-time PCR, performed according to manufacturer's protocol, using SYBR Green PCR Master Mix (Applied Biosystems) and the ABI Prism 7000 Sequence Detection System (Applied Biosystems). Primers were designed using the Primer3 Website and are listed on <xref ref-type="supplementary-material" rid="pone.0005926.s006">Table S2</xref>.</p><p>Samples were run in triplicate in a reaction volume of 25 &#x000b5;l. Amplification was carried out for 40 cycles, with denaturation at 95&#x000b0;C for 10 min during the first cycle and subsequently for 15 seconds, annealing and extension for 1 minute at 60&#x000b0;C. A dissociation temperature gradient was included at the end of the run. Gene expression was normalized according to GAPDH expression. Relative gene expression was calculated with the 2<sup>&#x02212;&#x00394;&#x00394;C</sup>T method <xref ref-type="bibr" rid="pone.0005926-Livak1">&#x0005b;65&#x0005d;</xref>.</p></sec><sec id="s4h"><title>TCR repertoire analysis</title><p>Qualitative analysis of CDR3 length for V&#x003b3;9-J&#x003b3;1/2, V&#x003b3;9-J&#x003b3;P and V&#x003b4;2-C&#x003b4; families was performed in triplicate on eosinophils and in &#x003b3;&#x003b4; T cells from the same donor (TcLand, Nantes, France) <xref ref-type="bibr" rid="pone.0005926-Douillard1">&#x0005b;66&#x0005d;</xref>. Briefly, cDNA was amplified by PCR using a C&#x003b3; or C&#x003b4; reverse primer and V&#x003b3;9 or V&#x003b4;2-specific forward primers, respectively. The amplifications were performed in a 384-Well GeneAmp&#x000ae; PCR System 9700 (Applied Biosystems, Foster City, CA). Briefly, each amplification product was used for an elongation reaction using a dye-labeled J&#x003b3; specific-labelled primer for the rearrangement analysis and C&#x003b4; labeled primer for the &#x003b4; chain analysis, then heat denatured, loaded at least in duplicate onto a sequencing analyzer (48-capillary 3730 DNA Analyzer - Applied Biosystems). Then, GeneMapper software (Applied Biosystems) was used to display the distribution profiles of CDR3 lengths, in amino acids, of the amplified and elongated products.</p></sec><sec id="s4i"><title>&#x003b3;&#x003b4;TCR junctional sequences analysis</title><p>V&#x003b4;1-J&#x003b4;3 and V&#x003b4;2-C&#x003b4; amplification products (400 bp) were cloned into a TA vector (pCR-TOPO, Invitrogen) using standard protocols. For each rearrangement, sequencing was performed on 5 randomly picked clones. TCR sequences were obtained from the IMGT website (imgt.cines.fr). Sequence alignments were performed using DNAstar software. GeneBank sequence accession numbers are: FJ890312 and FJ890313 respectively.</p></sec><sec id="s4j"><title><italic>In situ</italic> hybridisation</title><p>PCR products, amplified from purified &#x003b3;&#x003b4;TCR lymphocyte RNA, and corresponding to V&#x003b3;I-J&#x003b3;P, V&#x003b4;2-C&#x003b4; and V&#x003b4;1-J&#x003b4;4 rearrangements were cloned into the pCRII-TOPO vector (Invitrogen). Clones were isolated and sequenced on both strands. Clones corresponding to the published sequence were used to generate hybridization probes. Sense and anti-sense probes were synthesised from linearised plasmids using 350 &#x000b5;M digoxigenin-UTP (Roche) and SP6 or T7 polymerases as described <xref ref-type="bibr" rid="pone.0005926-Wilkinson1">&#x0005b;67&#x0005d;</xref>. <italic>In situ</italic> hybridisation was performed using a Discovery automat and corresponding kits (Ventana Medical Systems). Slides were incubated in EZprep buffer before processing with a standard RiboMap Kit. Slides were pre-treated 30 min with CC2 buffer, then 20 min with protease 3, followed by 6 h hybridization with sense or anti-sense probes (100 ng/slide). Slides were then washed twice 10 min in 2&#x000d7; SSC at 60&#x000b0;C, twice 10 min in 0.1&#x000d7; SSC at 60&#x000b0;C. Slides were incubated for 30 min with a mouse anti-digoxigenin antibody (Jackson ImmunoResearch) and then for 30 min with a rabbit anti-mouse antibody before treatment with UltraMap kit. Labelling was detected after a 150 min (V&#x003b4;2-C&#x003b4;), 110 min (V&#x003b3;I-J&#x003b3;P) or 90 min (V&#x003b4;1-J&#x003b4;4) incubation in the presence of NBT/BCIP substrate. Slides were counterstained for 1 h with Nuclear Fast Red and mounted in permanent mounting medium (Vector).</p></sec><sec id="s4k"><title>ROS production and EPO release</title><p>ROS production and EPO release were measured as described <xref ref-type="bibr" rid="pone.0005926-Legrand1">&#x0005b;61&#x0005d;</xref>. Wells were coated with 10 &#x000b5;g/ml anti-mouse IgG F(ab')<sub>2</sub> (Sigma) for 2 h at 37&#x000b0;C, followed by incubation with 10 &#x000b5;g/ml anti-CD3, anti-&#x003b3;&#x003b4;TCR, anti-V&#x003b4;1or isotype control mouse IgG<sub>1</sub> for 2 h at 37&#x000b0;C. Eosinophils (2&#x000d7;10<sup>6</sup>/ml) were added in the presence of luminol (8.3 &#x000b5;g/ml). Alternatively, eosinophils were stimulated with 50&#x02013;200 nM BrHPP, 5&#x02013;50 &#x000b5;M sec-butylamine (SBA) (Sigma) or IgA/anti-IgA immune complexes (incubation with 7.5 &#x000b5;g/ml secretory IgA for 1 hr then by addition of 10 &#x000b5;g/ml anti-IgA). Chemiluminescence was measured at 37&#x000b0;C for 5 sec/timepoint with a luminometer (Victor<sup>2</sup>&#x02122; Wallac). For EPO release, supernatants (50 &#x000b5;l) were transferred into a microtiterplate and luminol (50 &#x000b5;g/ml), D-luciferin (4&#x000d7;10<sup>&#x02212;5</sup>M) (Roche Diagnostics) and H<sub>2</sub>O<sub>2</sub> were injected.</p></sec><sec id="s4l"><title>EDN and cytokine release</title><p>Eosinophils (2&#x000d7;10<sup>6</sup>/ml) were activated with the same stimuli as for ROS production. After 18 h culture, supernatants were collected. EDN levels were measured by specific ELISA (MBL). The lower detection limit was 0.62 ng/ml. IFN&#x003b3; and TNF&#x003b1; cytokines were measured by specific ELISA (Diaclone). Detection limit was 5 pg/ml for IFN&#x003b3; and 8 pg/ml for TNF&#x003b1;.</p></sec><sec id="s4m"><title>Activation with Mycobacteria</title><p><italic>Mycobacterium bovis</italic>-BCG Pasteur strain was obtained from Dr C. Locht (Inserm U629, Institut Pasteur de Lille, France) and was grown in Sauton medium at 37&#x000b0;C. Eosinophils were incubated with various BCG numbers (Eosinophil/BCG: 20/1, 10/1 and 5/1). ROS and EPO release were determined as described above. For inhibition experiments, eosinophils (20/1 ratio) were incubated with a blocking anti-&#x003b3;&#x003b4;TCR mAb (10 &#x000b5;g/ml) or isotype control for 30 min at 37&#x000b0;C, before BCG addition.</p></sec><sec id="s4n"><title>Tumor cell apoptosis</title><p>Colo 205 cells were labelled with 10 &#x000b5;M PKH26 (Sigma) according to manufacturer's instructions. Then, eosinophil-mediated cytotoxicity against PKH-26-labelled Colo-205 (10 &#x000b5;M) was measured in complete medium at 1.6&#x000d7;10<sup>4</sup> targets/well into U-bottom plates containing eosinophils (25&#x02236;1 Effector:Target ratio) <xref ref-type="bibr" rid="pone.0005926-Legrand1">&#x0005b;61&#x0005d;</xref>. After different time points, apoptosis was measured by flow cytometry after annexinV-FITC staining (Pharmingen) for 15 min at RT. For inhibition experiments, blocking antibodies against &#x003b3;&#x003b4;TCR or isotype-matched control (10 &#x000b5;g/ml) were added to eosinophils immediately prior to the incubation in the presence of targets. In some experiments, eosinophils were preincubated for 30 min with 50 &#x000b5;M SBA or 20 mM TUBAg 1 before addition to the target cells.</p></sec><sec id="s4o"><title>Statistical analysis</title><p>Individual data or mean&#x000b1;S.E.M values were presented. All statistical analyses were performed using SPSS software. Normality of data samples was assessed with the Normality test of Shapiro and Wilk. Then parametric paired-samples Student's t-test was used to compare variables and the one-tailed statistical significance level was as represented on Figures.</p></sec></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0005926.s001"><label>Figure S1</label><caption><p>Gating strategy and specific identification of purified peripheral blood eosinophils in flow cytometry analysis. (A&#x02013;B) Gating of purified peripheral blood eosinophils on forward and side scatter parameters immediately after purification. (A) Ellipsoids circle the analyzed population. (B). Specificity of eosinophil identification by intracellular detection of EPO, MBP or MPO using PE- or biotin-conjugated specific antibodies (grey shaded histograms). Staining on purified neutrophils as well as gated lymphocytes and monocytes from purified PBMC is shown as control. Staining with control isotype matched antibodies is represented in white histograms.</p><p>(6.41 MB TIF)</p></caption><media xlink:href="pone.0005926.s001.tif" mimetype="image" mime-subtype="tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0005926.s002"><label>Figure S2</label><caption><p>Surface expression of CD3, &#x003b3;&#x003b4;TCR, Vgamma9, Vdelta2,Vdelta1, &#x003b1;&#x003b2;TCR, CD8 and NKG2D detected by flow cytometry in double staining on immune cell populations. (A) In vitro-generated BrHPP-induced gamma9 delta2 TCR<sup>&#x0002b;</sup> lymphocytes. (B) Scatter-gated lymphocytes from PBMC. (C) Scatter-gated monocytes from PBMC. (D) CD16<sup>&#x0002b;</sup>-purified blood neutrophils. Staining with control isotype matched antibodies is represented.</p><p>(4.23 MB TIF)</p></caption><media xlink:href="pone.0005926.s002.tif" mimetype="image" mime-subtype="tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0005926.s003"><label>Figure S3</label><caption><p>Surface expression of &#x003b3;&#x003b4;TCR/CD3 complex by human eosinophils following induction by a mycobacterial &#x003b3;&#x003b4;TCR ligand. (A&#x02013;B) CD3, &#x003b3;&#x003b4;TCR, &#x003b1;&#x003b2;TCR and CD8 surface expression on EPO<sup>&#x0002b;</sup>-purified peripheral blood eosinophils incubated with culture medium (A) or with 40 nM TubAg for 2 h (B). Staining with control isotype matched antibodies is represented.</p><p>(3.02 MB TIF)</p></caption><media xlink:href="pone.0005926.s003.tif" mimetype="image" mime-subtype="tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0005926.s004"><label>Figure S4</label><caption><p>Surface expression of CD3, &#x003b3;&#x003b4;TCR and CD8 on cord blood-derived eosinophils. Eosinophils derived from CD34<sup>&#x0002b;</sup> cord blood cells (day 21) were analysed for CD3, &#x003b3;&#x003b4;TCR and CD8 cell surface expression after gating on EPO<sup>&#x0002b;</sup> cells. Staining with control isotype antibodies is represented.</p><p>(1.28 MB TIF)</p></caption><media xlink:href="pone.0005926.s004.tif" mimetype="image" mime-subtype="tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0005926.s005"><label>Table S1</label><caption><p>List, and characteristics of antibody used in this manuscript. Mb: Membrane staining. IC: Intracellular staining</p><p>(0.06 MB DOC)</p></caption><media xlink:href="pone.0005926.s005.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0005926.s006"><label>Table S2</label><caption><p>Gene-specific primer sequences</p><p>(0.04 MB DOC)</p></caption><media xlink:href="pone.0005926.s006.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>The authors wish to thank M. Bonneville (Inserm, Nantes, France), J. Khalife (Inserm, Lille) for helpful advices. They are grateful to L. Prin (CHRU, Lille France) and the National Network on Hypereosinophilia for access to eosinophilic patients, C. Rouanet and C. Locht (Inserm, Lille, France) for providing BCG and technical suggestions and Dr D. Plager (Mayo Clinic, Rochester) for anti-MBP2 antibody. The authors also with to thank M. Delbecke and J. Bertout for their technical assistance.</p></ack><ref-list><title>References</title><ref id="pone.0005926-Giembycz1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Giembycz</surname><given-names>MA</given-names></name><name><surname>Lindsay</surname><given-names>MA</given-names></name></person-group><year>1999</year><article-title>Pharmacology of the eosinophil.</article-title><source>Pharmacol Rev</source><volume>51</volume><fpage>213</fpage><lpage>340</lpage><pub-id pub-id-type="pmid">10353986</pub-id></citation></ref><ref id="pone.0005926-Rothenberg1"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rothenberg</surname><given-names>ME</given-names></name><name><surname>Hogan</surname><given-names>SP</given-names></name></person-group><year>2006</year><article-title>The eosinophil.</article-title><source>Annu Rev Immunol</source><volume>24</volume><fpage>147</fpage><lpage>174</lpage><pub-id pub-id-type="pmid">16551246</pub-id></citation></ref><ref id="pone.0005926-Jacobsen1"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jacobsen</surname><given-names>EA</given-names></name><name><surname>Ochkur</surname><given-names>SI</given-names></name><name><surname>Pero</surname><given-names>RS</given-names></name><name><surname>Taranova</surname><given-names>AG</given-names></name><name><surname>Protheroe</surname><given-names>CA</given-names></name><etal/></person-group><year>2008</year><article-title>Allergic pulmonary inflammation in mice is dependent on eosinophil-induced recruitment of effector T cells.</article-title><source>J Exp Med</source><volume>205</volume><fpage>699</fpage><lpage>710</lpage><pub-id pub-id-type="pmid">18316417</pub-id></citation></ref><ref id="pone.0005926-Walsh1"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>ER</given-names></name><name><surname>Sahu</surname><given-names>N</given-names></name><name><surname>Kearley</surname><given-names>J</given-names></name><name><surname>Benjamin</surname><given-names>E</given-names></name><name><surname>Kang</surname><given-names>BH</given-names></name><etal/></person-group><year>2008</year><article-title>Strain-specific requirement for eosinophils in the recruitment of T cells to the lung during the development of allergic asthma.</article-title><source>J Exp Med</source><volume>205</volume><fpage>1285</fpage><lpage>1292</lpage><pub-id pub-id-type="pmid">18490489</pub-id></citation></ref><ref id="pone.0005926-Young1"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>JD</given-names></name><name><surname>Peterson</surname><given-names>CG</given-names></name><name><surname>Venge</surname><given-names>P</given-names></name><name><surname>Cohn</surname><given-names>ZA</given-names></name></person-group><year>1986</year><article-title>Mechanism of membrane damage mediated by human eosinophil cationic protein.</article-title><source>Nature</source><volume>321</volume><fpage>613</fpage><lpage>616</lpage><pub-id pub-id-type="pmid">2423882</pub-id></citation></ref><ref id="pone.0005926-Gounni1"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gounni</surname><given-names>AS</given-names></name><name><surname>Lamkhioued</surname><given-names>B</given-names></name><name><surname>Ochiai</surname><given-names>K</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Delaporte</surname><given-names>E</given-names></name><etal/></person-group><year>1994</year><article-title>High-affinity IgE receptor on eosinophils is involved in defence against parasites.</article-title><source>Nature</source><volume>367</volume><fpage>183</fpage><lpage>186</lpage><pub-id pub-id-type="pmid">8114916</pub-id></citation></ref><ref id="pone.0005926-Stenfeldt1"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stenfeldt</surname><given-names>AL</given-names></name><name><surname>Wenneras</surname><given-names>C</given-names></name></person-group><year>2004</year><article-title>Danger signals derived from stressed and necrotic epithelial cells activate human eosinophils.</article-title><source>Immunology</source><volume>112</volume><fpage>605</fpage><lpage>614</lpage><pub-id pub-id-type="pmid">15270732</pub-id></citation></ref><ref id="pone.0005926-Jacobsen2"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jacobsen</surname><given-names>EA</given-names></name><name><surname>Taranova</surname><given-names>AG</given-names></name><name><surname>Lee</surname><given-names>NA</given-names></name><name><surname>Lee</surname><given-names>JJ</given-names></name></person-group><year>2007</year><article-title>Eosinophils: singularly destructive effector cells or purveyors of immunoregulation?</article-title><source>J Allergy Clin Immunol</source><volume>119</volume><fpage>1313</fpage><lpage>1320</lpage><pub-id pub-id-type="pmid">17481717</pub-id></citation></ref><ref id="pone.0005926-Kayaba1"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kayaba</surname><given-names>H</given-names></name><name><surname>Dombrowicz</surname><given-names>D</given-names></name><name><surname>Woerly</surname><given-names>G</given-names></name><name><surname>Papin</surname><given-names>JP</given-names></name><name><surname>Loiseau</surname><given-names>S</given-names></name><etal/></person-group><year>2001</year><article-title>Human eosinophils and human high affinity IgE receptor transgenic mouse eosinophils express low levels of high affinity IgE receptor, but release IL-10 upon receptor activation.</article-title><source>J Immunol</source><volume>167</volume><fpage>995</fpage><lpage>1003</lpage><pub-id pub-id-type="pmid">11441108</pub-id></citation></ref><ref id="pone.0005926-Woerly1"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Woerly</surname><given-names>G</given-names></name><name><surname>Roger</surname><given-names>N</given-names></name><name><surname>Loiseau</surname><given-names>S</given-names></name><name><surname>Dombrowicz</surname><given-names>D</given-names></name><name><surname>Capron</surname><given-names>A</given-names></name><etal/></person-group><year>1999</year><article-title>Expression of CD28 and CD86 by human eosinophils and role in the secretion of type 1 cytokines (interleukin 2 and interferon gamma): inhibition by Immunoglobulin A complexes.</article-title><source>J Exp Med</source><volume>190</volume><fpage>487</fpage><lpage>495</lpage><pub-id pub-id-type="pmid">10449520</pub-id></citation></ref><ref id="pone.0005926-Woerly2"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Woerly</surname><given-names>G</given-names></name><name><surname>Lacy</surname><given-names>P</given-names></name><name><surname>Younes</surname><given-names>AB</given-names></name><name><surname>Roger</surname><given-names>N</given-names></name><name><surname>Loiseau</surname><given-names>S</given-names></name><etal/></person-group><year>2002</year><article-title>Human eosinophils express and release IL-13 following CD28-dependent activation.</article-title><source>J Leukoc Biol</source><volume>72</volume><fpage>769</fpage><lpage>779</lpage><pub-id pub-id-type="pmid">12377947</pub-id></citation></ref><ref id="pone.0005926-Melo1"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Melo</surname><given-names>RC</given-names></name><name><surname>Spencer</surname><given-names>LA</given-names></name><name><surname>Dvorak</surname><given-names>AM</given-names></name><name><surname>Weller</surname><given-names>PF</given-names></name></person-group><year>2008</year><article-title>Mechanisms of eosinophil secretion: large vesiculotubular carriers mediate transport and release of granule-derived cytokines and other proteins.</article-title><source>J Leukoc Biol</source><volume>83</volume><fpage>229</fpage><lpage>236</lpage><pub-id pub-id-type="pmid">17875811</pub-id></citation></ref><ref id="pone.0005926-Lucey1"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lucey</surname><given-names>DR</given-names></name><name><surname>Nicholson-Weller</surname><given-names>A</given-names></name><name><surname>Weller</surname><given-names>PF</given-names></name></person-group><year>1989</year><article-title>Mature human eosinophils have the capacity to express HLA-DR.</article-title><source>Proc Natl Acad Sci U S A</source><volume>86</volume><fpage>1348</fpage><lpage>1351</lpage><pub-id pub-id-type="pmid">2919183</pub-id></citation></ref><ref id="pone.0005926-Seton1"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Seton</surname><given-names>K</given-names></name><name><surname>Hakansson</surname><given-names>L</given-names></name><name><surname>Carlson</surname><given-names>M</given-names></name><name><surname>Stalenheim</surname><given-names>G</given-names></name><name><surname>Venge</surname><given-names>P</given-names></name></person-group><year>2003</year><article-title>Apoptotic eosinophils express IL-2R chains alpha and beta and co-stimulatory molecules CD28 and CD86.</article-title><source>Respir Med</source><volume>97</volume><fpage>893</fpage><lpage>902</lpage><pub-id pub-id-type="pmid">12924515</pub-id></citation></ref><ref id="pone.0005926-Shi1"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>HZ</given-names></name><name><surname>Humbles</surname><given-names>A</given-names></name><name><surname>Gerard</surname><given-names>C</given-names></name><name><surname>Jin</surname><given-names>Z</given-names></name><name><surname>Weller</surname><given-names>PF</given-names></name></person-group><year>2000</year><article-title>Lymph node trafficking and antigen presentation by endobronchial eosinophils.</article-title><source>J Clin Invest</source><volume>105</volume><fpage>945</fpage><lpage>953</lpage><pub-id pub-id-type="pmid">10749574</pub-id></citation></ref><ref id="pone.0005926-Plumas1"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Plumas</surname><given-names>J</given-names></name><name><surname>Gruart</surname><given-names>V</given-names></name><name><surname>Aldebert</surname><given-names>D</given-names></name><name><surname>Truong</surname><given-names>MJ</given-names></name><name><surname>Capron</surname><given-names>M</given-names></name><etal/></person-group><year>1991</year><article-title>Human eosinophils from hypereosinophilic patients spontaneously express the p55 but not the p75 interleukin 2 receptor subunit.</article-title><source>Eur J Immunol</source><volume>21</volume><fpage>1265</fpage><lpage>1270</lpage><pub-id pub-id-type="pmid">2037012</pub-id></citation></ref><ref id="pone.0005926-Simon1"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Simon</surname><given-names>HU</given-names></name><name><surname>Plotz</surname><given-names>S</given-names></name><name><surname>Simon</surname><given-names>D</given-names></name><name><surname>Seitzer</surname><given-names>U</given-names></name><name><surname>Braathen</surname><given-names>LR</given-names></name><etal/></person-group><year>2003</year><article-title>Interleukin-2 primes eosinophil degranulation in hypereosinophilia and Wells' syndrome.</article-title><source>Eur J Immunol</source><volume>33</volume><fpage>834</fpage><lpage>839</lpage><pub-id pub-id-type="pmid">12672048</pub-id></citation></ref><ref id="pone.0005926-Lucey2"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lucey</surname><given-names>DR</given-names></name><name><surname>Dorsky</surname><given-names>DI</given-names></name><name><surname>Nicholson-Weller</surname><given-names>A</given-names></name><name><surname>Weller</surname><given-names>PF</given-names></name></person-group><year>1989</year><article-title>Human eosinophils express CD4 protein and bind human immunodeficiency virus 1 gp120.</article-title><source>J Exp Med</source><volume>169</volume><fpage>327</fpage><lpage>332</lpage><pub-id pub-id-type="pmid">2783333</pub-id></citation></ref><ref id="pone.0005926-Munitz1"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Munitz</surname><given-names>A</given-names></name><name><surname>Bachelet</surname><given-names>I</given-names></name><name><surname>Fraenkel</surname><given-names>S</given-names></name><name><surname>Katz</surname><given-names>G</given-names></name><name><surname>Mandelboim</surname><given-names>O</given-names></name><etal/></person-group><year>2005</year><article-title>2B4 (CD244) is expressed and functional on human eosinophils.</article-title><source>J Immunol</source><volume>174</volume><fpage>110</fpage><lpage>118</lpage><pub-id pub-id-type="pmid">15611233</pub-id></citation></ref><ref id="pone.0005926-Rowley1"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rowley</surname><given-names>AF</given-names></name><name><surname>Page</surname><given-names>M</given-names></name></person-group><year>1985</year><article-title>Ultrastructural, cytochemical and functional studies on the eosinophilic granulocytes of larval lampreys.</article-title><source>Cell Tissue Res</source><volume>240</volume><fpage>705</fpage><lpage>709</lpage></citation></ref><ref id="pone.0005926-Svensson1"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Svensson</surname><given-names>L</given-names></name><name><surname>Redvall</surname><given-names>E</given-names></name><name><surname>Bjorn</surname><given-names>C</given-names></name><name><surname>Karlsson</surname><given-names>J</given-names></name><name><surname>Bergin</surname><given-names>AM</given-names></name><etal/></person-group><year>2007</year><article-title>House dust mite allergen activates human eosinophils via formyl peptide receptor and formyl peptide receptor-like 1.</article-title><source>Eur J Immunol</source><volume>37</volume><fpage>1966</fpage><lpage>1977</lpage><pub-id pub-id-type="pmid">17559171</pub-id></citation></ref><ref id="pone.0005926-Miike1"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miike</surname><given-names>S</given-names></name><name><surname>McWilliam</surname><given-names>AS</given-names></name><name><surname>Kita</surname><given-names>H</given-names></name></person-group><year>2001</year><article-title>Trypsin induces activation and inflammatory mediator release from human eosinophils through protease-activated receptor-2.</article-title><source>J Immunol</source><volume>167</volume><fpage>6615</fpage><lpage>6622</lpage><pub-id pub-id-type="pmid">11714832</pub-id></citation></ref><ref id="pone.0005926-Bolton1"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bolton</surname><given-names>SJ</given-names></name><name><surname>McNulty</surname><given-names>CA</given-names></name><name><surname>Thomas</surname><given-names>RJ</given-names></name><name><surname>Hewitt</surname><given-names>CR</given-names></name><name><surname>Wardlaw</surname><given-names>AJ</given-names></name></person-group><year>2003</year><article-title>Expression of and functional responses to protease-activated receptors on human eosinophils.</article-title><source>J Leukoc Biol</source><volume>74</volume><fpage>60</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">12832443</pub-id></citation></ref><ref id="pone.0005926-Driss1"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Driss</surname><given-names>V</given-names></name><name><surname>Legrand</surname><given-names>F</given-names></name><name><surname>Hermann</surname><given-names>E</given-names></name><name><surname>Loiseau</surname><given-names>S</given-names></name><name><surname>Guerardel</surname><given-names>Y</given-names></name><etal/></person-group><year>2008</year><article-title>TLR2-dependent eosinophil interactions with mycobacteria : role of alpha-defensins.</article-title><source>Blood in press</source></citation></ref><ref id="pone.0005926-Nagase1"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nagase</surname><given-names>H</given-names></name><name><surname>Okugawa</surname><given-names>S</given-names></name><name><surname>Ota</surname><given-names>Y</given-names></name><name><surname>Yamaguchi</surname><given-names>M</given-names></name><name><surname>Tomizawa</surname><given-names>H</given-names></name><etal/></person-group><year>2003</year><article-title>Expression and function of Toll-like receptors in eosinophils: activation by Toll-like receptor 7 ligand.</article-title><source>J Immunol</source><volume>171</volume><fpage>3977</fpage><lpage>3982</lpage><pub-id pub-id-type="pmid">14530316</pub-id></citation></ref><ref id="pone.0005926-Phipps1"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Phipps</surname><given-names>S</given-names></name><name><surname>Lam</surname><given-names>CE</given-names></name><name><surname>Mahalingam</surname><given-names>S</given-names></name><name><surname>Newhouse</surname><given-names>M</given-names></name><name><surname>Ramirez</surname><given-names>R</given-names></name><etal/></person-group><year>2007</year><article-title>Eosinophils contribute to innate antiviral immunity and promote clearance of respiratory syncytial virus.</article-title><source>Blood</source><volume>110</volume><fpage>1578</fpage><lpage>1586</lpage><pub-id pub-id-type="pmid">17495130</pub-id></citation></ref><ref id="pone.0005926-Yousefi1"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yousefi</surname><given-names>S</given-names></name><name><surname>Gold</surname><given-names>JA</given-names></name><name><surname>Andina</surname><given-names>N</given-names></name><name><surname>Lee</surname><given-names>JJ</given-names></name><name><surname>Kelly</surname><given-names>AM</given-names></name><etal/></person-group><year>2008</year><article-title>Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense.</article-title><source>Nat Med</source><volume>14</volume><fpage>949</fpage><lpage>953</lpage><pub-id pub-id-type="pmid">18690244</pub-id></citation></ref><ref id="pone.0005926-Tepper1"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tepper</surname><given-names>RI</given-names></name><name><surname>Coffman</surname><given-names>RL</given-names></name><name><surname>Leder</surname><given-names>P</given-names></name></person-group><year>1992</year><article-title>An eosinophil-dependent mechanism for the antitumor effect of interleukin-4.</article-title><source>Science</source><volume>257</volume><fpage>548</fpage><lpage>551</lpage><pub-id pub-id-type="pmid">1636093</pub-id></citation></ref><ref id="pone.0005926-Tepper2"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tepper</surname><given-names>RI</given-names></name></person-group><year>1994</year><article-title>The eosinophil-mediated antitumor activity of interleukin-4.</article-title><source>J Allergy Clin Immunol</source><volume>94</volume><fpage>1225</fpage><lpage>1231</lpage><pub-id pub-id-type="pmid">7798564</pub-id></citation></ref><ref id="pone.0005926-Brandes1"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brandes</surname><given-names>M</given-names></name><name><surname>Willimann</surname><given-names>K</given-names></name><name><surname>Moser</surname><given-names>B</given-names></name></person-group><year>2005</year><article-title>Professional antigen-presentation function by human gammadelta T Cells.</article-title><source>Science</source><volume>309</volume><fpage>264</fpage><lpage>268</lpage><pub-id pub-id-type="pmid">15933162</pub-id></citation></ref><ref id="pone.0005926-Hayday1"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hayday</surname><given-names>AC</given-names></name></person-group><year>2000</year><article-title>Gamma delta cells: a right time and a right place for a conserved third way of protection.</article-title><source>Annu Rev Immunol</source><volume>18</volume><fpage>975</fpage><lpage>1026</lpage><pub-id pub-id-type="pmid">10837080</pub-id></citation></ref><ref id="pone.0005926-Carding1"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carding</surname><given-names>SR</given-names></name><name><surname>Egan</surname><given-names>PJ</given-names></name></person-group><year>2002</year><article-title>Gamma delta T cells: functional plasticity and heterogeneity.</article-title><source>Nat Rev Immunol</source><volume>2</volume><fpage>336</fpage><lpage>345</lpage><pub-id pub-id-type="pmid">12033739</pub-id></citation></ref><ref id="pone.0005926-Metso1"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Metso</surname><given-names>T</given-names></name><name><surname>Venge</surname><given-names>P</given-names></name><name><surname>Haahtela</surname><given-names>T</given-names></name><name><surname>Peterson</surname><given-names>CG</given-names></name><name><surname>Seveus</surname><given-names>L</given-names></name></person-group><year>2002</year><article-title>Cell specific markers for eosinophils and neutrophils in sputum and bronchoalveolar lavage fluid of patients with respiratory conditions and healthy subjects.</article-title><source>Thorax</source><volume>57</volume><fpage>449</fpage><lpage>451</lpage><pub-id pub-id-type="pmid">11978925</pub-id></citation></ref><ref id="pone.0005926-Puellmann1"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Puellmann</surname><given-names>K</given-names></name><name><surname>Kaminski</surname><given-names>WE</given-names></name><name><surname>Vogel</surname><given-names>M</given-names></name><name><surname>Nebe</surname><given-names>CT</given-names></name><name><surname>Schroeder</surname><given-names>J</given-names></name><etal/></person-group><year>2006</year><article-title>A variable immunoreceptor in a subpopulation of human neutrophils.</article-title><source>Proc Natl Acad Sci U S A</source><volume>103</volume><fpage>14441</fpage><lpage>14446</lpage><pub-id pub-id-type="pmid">16983085</pub-id></citation></ref><ref id="pone.0005926-Boullier1"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boullier</surname><given-names>S</given-names></name><name><surname>Poquet</surname><given-names>Y</given-names></name><name><surname>Halary</surname><given-names>F</given-names></name><name><surname>Bonneville</surname><given-names>M</given-names></name><name><surname>Fournie</surname><given-names>JJ</given-names></name><etal/></person-group><year>1998</year><article-title>Phosphoantigen activation induces surface translocation of intracellular CD94/NKG2A class I receptor on CD94- peripheral Vgamma9 Vdelta2 T cells but not on CD94- thymic or mature gammadelta T cell clones.</article-title><source>Eur J Immunol</source><volume>28</volume><fpage>3399</fpage><lpage>3410</lpage><pub-id pub-id-type="pmid">9842883</pub-id></citation></ref><ref id="pone.0005926-Constant1"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Constant</surname><given-names>P</given-names></name><name><surname>Davodeau</surname><given-names>F</given-names></name><name><surname>Peyrat</surname><given-names>MA</given-names></name><name><surname>Poquet</surname><given-names>Y</given-names></name><name><surname>Puzo</surname><given-names>G</given-names></name><etal/></person-group><year>1994</year><article-title>Stimulation of human gamma delta T cells by nonpeptidic mycobacterial ligands.</article-title><source>Science</source><volume>264</volume><fpage>267</fpage><lpage>270</lpage><pub-id pub-id-type="pmid">8146660</pub-id></citation></ref><ref id="pone.0005926-Espinosa1"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Espinosa</surname><given-names>E</given-names></name><name><surname>Belmant</surname><given-names>C</given-names></name><name><surname>Pont</surname><given-names>F</given-names></name><name><surname>Luciani</surname><given-names>B</given-names></name><name><surname>Poupot</surname><given-names>R</given-names></name><etal/></person-group><year>2001</year><article-title>Chemical synthesis and biological activity of bromohydrin pyrophosphate, a potent stimulator of human gamma delta T cells.</article-title><source>J Biol Chem</source><volume>276</volume><fpage>18337</fpage><lpage>18344</lpage><pub-id pub-id-type="pmid">11279081</pub-id></citation></ref><ref id="pone.0005926-Thompson1"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>K</given-names></name><name><surname>Rojas-Navea</surname><given-names>J</given-names></name><name><surname>Rogers</surname><given-names>MJ</given-names></name></person-group><year>2006</year><article-title>Alkylamines cause Vgamma9Vdelta2 T-cell activation and proliferation by inhibiting the mevalonate pathway.</article-title><source>Blood</source><volume>107</volume><fpage>651</fpage><lpage>654</lpage><pub-id pub-id-type="pmid">16179378</pub-id></citation></ref><ref id="pone.0005926-Lasco1"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lasco</surname><given-names>TM</given-names></name><name><surname>Turner</surname><given-names>OC</given-names></name><name><surname>Cassone</surname><given-names>L</given-names></name><name><surname>Sugawara</surname><given-names>I</given-names></name><name><surname>Yamada</surname><given-names>H</given-names></name><etal/></person-group><year>2004</year><article-title>Rapid accumulation of eosinophils in lung lesions in guinea pigs infected with Mycobacterium tuberculosis.</article-title><source>Infect Immun</source><volume>72</volume><fpage>1147</fpage><lpage>1149</lpage><pub-id pub-id-type="pmid">14742563</pub-id></citation></ref><ref id="pone.0005926-Groh1"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Groh</surname><given-names>V</given-names></name><name><surname>Steinle</surname><given-names>A</given-names></name><name><surname>Bauer</surname><given-names>S</given-names></name><name><surname>Spies</surname><given-names>T</given-names></name></person-group><year>1998</year><article-title>Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells.</article-title><source>Science</source><volume>279</volume><fpage>1737</fpage><lpage>1740</lpage><pub-id pub-id-type="pmid">9497295</pub-id></citation></ref><ref id="pone.0005926-Hayday2"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hayday</surname><given-names>A</given-names></name><name><surname>Tigelaar</surname><given-names>R</given-names></name></person-group><year>2003</year><article-title>Immunoregulation in the tissues by gammadelta T cells.</article-title><source>Nat Rev Immunol</source><volume>3</volume><fpage>233</fpage><lpage>242</lpage><pub-id pub-id-type="pmid">12658271</pub-id></citation></ref><ref id="pone.0005926-Rand1"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rand</surname><given-names>TH</given-names></name><name><surname>Silberstein</surname><given-names>DS</given-names></name><name><surname>Kornfeld</surname><given-names>H</given-names></name><name><surname>Weller</surname><given-names>PF</given-names></name></person-group><year>1991</year><article-title>Human eosinophils express functional interleukin 2 receptors.</article-title><source>J Clin Invest</source><volume>88</volume><fpage>825</fpage><lpage>832</lpage><pub-id pub-id-type="pmid">1885772</pub-id></citation></ref><ref id="pone.0005926-Krejci1"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Krejci</surname><given-names>O</given-names></name><name><surname>Prouzova</surname><given-names>Z</given-names></name><name><surname>Horvath</surname><given-names>O</given-names></name><name><surname>Trka</surname><given-names>J</given-names></name><name><surname>Hrusak</surname><given-names>O</given-names></name></person-group><year>2003</year><article-title>Cutting edge: TCR delta gene is frequently rearranged in adult B lymphocytes.</article-title><source>J Immunol</source><volume>171</volume><fpage>524</fpage><lpage>527</lpage><pub-id pub-id-type="pmid">12847212</pub-id></citation></ref><ref id="pone.0005926-Fronkova1"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fronkova</surname><given-names>E</given-names></name><name><surname>Krejci</surname><given-names>O</given-names></name><name><surname>Kalina</surname><given-names>T</given-names></name><name><surname>Horvath</surname><given-names>O</given-names></name><name><surname>Trka</surname><given-names>J</given-names></name><etal/></person-group><year>2005</year><article-title>Lymphoid Differentiation Pathways Can Be Traced by TCR {delta} Rearrangements.</article-title><source>J Immunol</source><volume>175</volume><fpage>2495</fpage><lpage>2500</lpage><pub-id pub-id-type="pmid">16081821</pub-id></citation></ref><ref id="pone.0005926-Couedel1"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Couedel</surname><given-names>C</given-names></name><name><surname>Lippert</surname><given-names>E</given-names></name><name><surname>Bernardeau</surname><given-names>K</given-names></name><name><surname>Bonneville</surname><given-names>M</given-names></name><name><surname>Davodeau</surname><given-names>F</given-names></name></person-group><year>2004</year><article-title>Allelic exclusion at the TCR delta locus and commitment to gamma delta lineage: different modalities apply to distinct human gamma delta subsets.</article-title><source>J Immunol</source><volume>172</volume><fpage>5544</fpage><lpage>5552</lpage><pub-id pub-id-type="pmid">15100297</pub-id></citation></ref><ref id="pone.0005926-Shigematsu1"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shigematsu</surname><given-names>H</given-names></name><name><surname>Reizis</surname><given-names>B</given-names></name><name><surname>Iwasaki</surname><given-names>H</given-names></name><name><surname>Mizuno</surname><given-names>S</given-names></name><name><surname>Hu</surname><given-names>D</given-names></name><etal/></person-group><year>2004</year><article-title>Plasmacytoid dendritic cells activate lymphoid-specific genetic programs irrespective of their cellular origin.</article-title><source>Immunity</source><volume>21</volume><fpage>43</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">15345219</pub-id></citation></ref><ref id="pone.0005926-Kawamoto1"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kawamoto</surname><given-names>H</given-names></name></person-group><year>2006</year><article-title>A close developmental relationship between the lymphoid and myeloid lineages.</article-title><source>Trends Immunol</source><volume>27</volume><fpage>169</fpage><lpage>175</lpage><pub-id pub-id-type="pmid">16515884</pub-id></citation></ref><ref id="pone.0005926-Xie1"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>H</given-names></name><name><surname>Ye</surname><given-names>M</given-names></name><name><surname>Feng</surname><given-names>R</given-names></name><name><surname>Graf</surname><given-names>T</given-names></name></person-group><year>2004</year><article-title>Stepwise reprogramming of B cells into macrophages.</article-title><source>Cell</source><volume>117</volume><fpage>663</fpage><lpage>676</lpage><pub-id pub-id-type="pmid">15163413</pub-id></citation></ref><ref id="pone.0005926-Sehmi1"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sehmi</surname><given-names>R</given-names></name><name><surname>Denburg</surname><given-names>JA</given-names></name></person-group><year>2000</year><article-title>Differentiation of human eosinophils. Role in allergic inflammation.</article-title><source>Chem Immunol</source><volume>76</volume><fpage>29</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">10761303</pub-id></citation></ref><ref id="pone.0005926-Lee1"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JJ</given-names></name><name><surname>Lee</surname><given-names>NA</given-names></name></person-group><year>2005</year><article-title>Eosinophil degranulation: an evolutionary vestige or a universally destructive effector function?</article-title><source>Clin Exp Allergy</source><volume>35</volume><fpage>986</fpage><lpage>994</lpage><pub-id pub-id-type="pmid">16120079</pub-id></citation></ref><ref id="pone.0005926-deAndres1"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Andres</surname><given-names>B</given-names></name><name><surname>Rakasz</surname><given-names>E</given-names></name><name><surname>Hagen</surname><given-names>M</given-names></name><name><surname>McCormik</surname><given-names>ML</given-names></name><name><surname>Mueller</surname><given-names>AL</given-names></name><etal/></person-group><year>1997</year><article-title>Lack of Fc-epsilon receptors on murine eosinophils: implications for the functional significance of elevated IgE and eosinophils in parasitic infections.</article-title><source>Blood</source><volume>89</volume><fpage>3826</fpage><lpage>3836</lpage><pub-id pub-id-type="pmid">9160690</pub-id></citation></ref><ref id="pone.0005926-Decot1"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Decot</surname><given-names>V</given-names></name><name><surname>Woerly</surname><given-names>G</given-names></name><name><surname>Loyens</surname><given-names>M</given-names></name><name><surname>Loiseau</surname><given-names>S</given-names></name><name><surname>Quatannens</surname><given-names>B</given-names></name><etal/></person-group><year>2005</year><article-title>Heterogeneity of expression of IgA receptors by human, mouse, and rat eosinophils.</article-title><source>J Immunol</source><volume>174</volume><fpage>628</fpage><lpage>635</lpage><pub-id pub-id-type="pmid">15634880</pub-id></citation></ref><ref id="pone.0005926-Jameson1"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jameson</surname><given-names>J</given-names></name><name><surname>Havran</surname><given-names>WL</given-names></name></person-group><year>2007</year><article-title>Skin gammadelta T-cell functions in homeostasis and wound healing.</article-title><source>Immunol Rev</source><volume>215</volume><fpage>114</fpage><lpage>122</lpage><pub-id pub-id-type="pmid">17291283</pub-id></citation></ref><ref id="pone.0005926-OBrien1"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O'Brien</surname><given-names>RL</given-names></name><name><surname>Roark</surname><given-names>CL</given-names></name><name><surname>Jin</surname><given-names>N</given-names></name><name><surname>Aydintug</surname><given-names>MK</given-names></name><name><surname>French</surname><given-names>JD</given-names></name><etal/></person-group><year>2007</year><article-title>Gammadelta T-cell receptors: functional correlations.</article-title><source>Immunol Rev</source><volume>215</volume><fpage>77</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">17291280</pub-id></citation></ref><ref id="pone.0005926-Hsu1"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>SY</given-names></name><name><surname>Hsu</surname><given-names>HF</given-names></name><name><surname>Mitros</surname><given-names>FA</given-names></name><name><surname>Helms</surname><given-names>CM</given-names></name><name><surname>Solomon</surname><given-names>RI</given-names></name></person-group><year>1980</year><article-title>Eosinophils as effector cells in the destruction of Schistosoma mansoni eggs in granulomas.</article-title><source>Ann Trop Med Parasitol</source><volume>74</volume><fpage>179</fpage><lpage>183</lpage><pub-id pub-id-type="pmid">7436603</pub-id></citation></ref><ref id="pone.0005926-Choy1"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Choy</surname><given-names>MY</given-names></name><name><surname>Walker-Smith</surname><given-names>JA</given-names></name><name><surname>Williams</surname><given-names>CB</given-names></name><name><surname>MacDonald</surname><given-names>TT</given-names></name></person-group><year>1990</year><article-title>Activated eosinophils in chronic inflammatory bowel disease.</article-title><source>Lancet</source><volume>336</volume><fpage>126</fpage><lpage>127</lpage><pub-id pub-id-type="pmid">1975316</pub-id></citation></ref><ref id="pone.0005926-Borelli1"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Borelli</surname><given-names>V</given-names></name><name><surname>Vita</surname><given-names>F</given-names></name><name><surname>Shankar</surname><given-names>S</given-names></name><name><surname>Soranzo</surname><given-names>MR</given-names></name><name><surname>Banfi</surname><given-names>E</given-names></name><etal/></person-group><year>2003</year><article-title>Human eosinophil peroxidase induces surface alteration, killing, and lysis of Mycobacterium tuberculosis.</article-title><source>Infect Immun</source><volume>71</volume><fpage>605</fpage><lpage>613</lpage><pub-id pub-id-type="pmid">12540536</pub-id></citation></ref><ref id="pone.0005926-Thedrez1"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thedrez</surname><given-names>A</given-names></name><name><surname>Sabourin</surname><given-names>C</given-names></name><name><surname>Gertner</surname><given-names>J</given-names></name><name><surname>Devilder</surname><given-names>MC</given-names></name><name><surname>Allain-Maillet</surname><given-names>S</given-names></name><etal/></person-group><year>2007</year><article-title>Self/non-self discrimination by human gammadelta T cells: simple solutions for a complex issue?</article-title><source>Immunol Rev</source><volume>215</volume><fpage>123</fpage><lpage>135</lpage><pub-id pub-id-type="pmid">17291284</pub-id></citation></ref><ref id="pone.0005926-FernandezAcenero1"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fernandez-Acenero</surname><given-names>MJ</given-names></name><name><surname>Galindo-Gallego</surname><given-names>M</given-names></name><name><surname>Sanz</surname><given-names>J</given-names></name><name><surname>Aljama</surname><given-names>A</given-names></name></person-group><year>2000</year><article-title>Prognostic influence of tumor-associated eosinophilic infiltrate in colorectal carcinoma.</article-title><source>Cancer</source><volume>88</volume><fpage>1544</fpage><lpage>1548</lpage><pub-id pub-id-type="pmid">10738211</pub-id></citation></ref><ref id="pone.0005926-Bennouna1"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bennouna</surname><given-names>J</given-names></name><name><surname>Bompas</surname><given-names>E</given-names></name><name><surname>Neidhardt</surname><given-names>EM</given-names></name><name><surname>Rolland</surname><given-names>F</given-names></name><name><surname>Philip</surname><given-names>I</given-names></name><etal/></person-group><year>2008</year><article-title>Phase-I study of Innacell gammadeltatrade mark, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma.</article-title><source>Cancer Immunol Immunother</source><volume>57</volume><fpage>1599</fpage><lpage>1609</lpage><pub-id pub-id-type="pmid">18301889</pub-id></citation></ref><ref id="pone.0005926-Legrand1"><label>61</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Legrand</surname><given-names>F</given-names></name><name><surname>Woerly</surname><given-names>G</given-names></name><name><surname>Driss</surname><given-names>V</given-names></name><name><surname>Capron</surname><given-names>M</given-names></name></person-group><year>2007</year><article-title>Innate immune functions of eosinophils. From antiparasite to antitumor cells.</article-title><person-group person-group-type="editor"><name><surname>Ewbank</surname><given-names>J</given-names></name><name><surname>Vivier</surname><given-names>E</given-names></name></person-group><source>Methods in molecular Biology</source><publisher-loc>Totowa NJ</publisher-loc><publisher-name>Humana Press</publisher-name><fpage>215</fpage><lpage>240</lpage></citation></ref><ref id="pone.0005926-Plager1"><label>62</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Plager</surname><given-names>DA</given-names></name><name><surname>Loegering</surname><given-names>DA</given-names></name><name><surname>Checkel</surname><given-names>JL</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Kephart</surname><given-names>GM</given-names></name><etal/></person-group><year>2006</year><article-title>Major basic protein homolog (MBP2): a specific human eosinophil marker.</article-title><source>J Immunol</source><volume>177</volume><fpage>7340</fpage><lpage>7345</lpage><pub-id pub-id-type="pmid">17082653</pub-id></citation></ref><ref id="pone.0005926-Herzenberg1"><label>63</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Herzenberg</surname><given-names>LA</given-names></name><name><surname>Tung</surname><given-names>J</given-names></name><name><surname>Moore</surname><given-names>WA</given-names></name><name><surname>Herzenberg</surname><given-names>LA</given-names></name><name><surname>Parks</surname><given-names>DR</given-names></name></person-group><year>2006</year><article-title>Interpreting flow cytometry data: a guide for the perplexed.</article-title><source>Nat Immunol</source><volume>7</volume><fpage>681</fpage><lpage>685</lpage><pub-id pub-id-type="pmid">16785881</pub-id></citation></ref><ref id="pone.0005926-Hayes1"><label>64</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hayes</surname><given-names>SM</given-names></name><name><surname>Love</surname><given-names>PE</given-names></name></person-group><year>2002</year><article-title>Distinct structure and signaling potential of the gamma delta TCR complex.</article-title><source>Immunity</source><volume>16</volume><fpage>827</fpage><lpage>838</lpage><pub-id pub-id-type="pmid">12121664</pub-id></citation></ref><ref id="pone.0005926-Livak1"><label>65</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Livak</surname><given-names>KJ</given-names></name><name><surname>Schmittgen</surname><given-names>TD</given-names></name></person-group><year>2001</year><article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.</article-title><source>Methods</source><volume>25</volume><fpage>402</fpage><lpage>408</lpage><pub-id pub-id-type="pmid">11846609</pub-id></citation></ref><ref id="pone.0005926-Douillard1"><label>66</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Douillard</surname><given-names>P</given-names></name><name><surname>Josien</surname><given-names>R</given-names></name><name><surname>Pannetier</surname><given-names>C</given-names></name><name><surname>Bonneville</surname><given-names>M</given-names></name><name><surname>Soulillou</surname><given-names>JP</given-names></name><etal/></person-group><year>1998</year><article-title>Selection of T cell clones with restricted TCR-CDR3 lengths during in vitro and in vivo alloresponses.</article-title><source>Int Immunol</source><volume>10</volume><fpage>71</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">9488157</pub-id></citation></ref><ref id="pone.0005926-Wilkinson1"><label>67</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilkinson</surname><given-names>DG</given-names></name><name><surname>Nieto</surname><given-names>MA</given-names></name></person-group><year>1993</year><article-title>Detection of messenger RNA by in situ hybridization to tissue sections and whole mounts.</article-title><source>Methods Enzymol</source><volume>225</volume><fpage>361</fpage><lpage>373</lpage><pub-id pub-id-type="pmid">8231863</pub-id></citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>Work was funded by Inserm (French National Institutes for Health and Medical Reserach), Pasteur Institute Lille (a not for profit Research Institute), University Lille - Nord de France and ANR (French National Research Agency). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></back></article> 